Since the VEGF levels increase as DR progresses (Adamis et al., 1994; Aiello et al., 1994; Amin et al., 1997; Lutty et al., 1996), VEGF is very important in the development and progression of DR. VEGF is also a vascular permeability factor and plays an important role in the development of diabetic macular edema (DME) (Mathews et al., 1997). Based on these observations, several anti-VEGF agents such as an anti-VEGF antibody (Adamis et al., 1996), soluble VEGF-receptor chimeric proteins (Aiello et al., 1995), and antisense phosphorothioate oligodeoxynucleotides against VEGF (Robinson et al., 1996) have been tested in an animal model of retinal neovascularization mimicking DR. The results were very promising. Based on these favorable results in animal studies, several clinical studies have been undertaken to evaluate treatment of DME using an anti-VEGF antibody. The RESOLVE Study evaluated the safety and efficacy of intravitreal ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) for treating patients with DME (Massin et al., 2010). Ranibizumab is a fully humanized monoclonal antibody fragment, which binds to multiple variants of VEGF-A, and is approved to treat age-related macular degeneration. The results indicated that intravitreal ranibizumab improves visual acuity and reduces macular thickness in DME. The Diabetic Retinopathy Clinical Research Network (DRCR.net) is evaluating and comparing several medical treatments for DME. The DRCR.net is a collaborative network formed in September 2002 that is dedicated to facilitating multicenter clinical studies of DR, DME, and associated conditions. Currently, there are more than 109 participating sites with over 320 physicians throughout the United States (http://drcrnet.jaeb.org/). The DRCR.net reported that intravitreal ranibizumab combined with laser treatment is more effective than laser treatment with or without triamcinolone. The anti-VEGF agents inhibit VEGF and increase capillary permeability. Macular edema is resolved by blocking increased capillary permeability. However, a drawback of the anti-VEGF agents is that they do not have long-term efficacy, so repeated injections are usually required. Moreover, a 2% prevalence of endophthalmitis over 12 months in the RESOLVE Study is worrisome. To minimize the number of intravitreal injections, gene therapy using a safe virus vector, such as an adeno-associated virus (Ideno et al., 2007), may be a future

Good glycemic control is the most important factor for preventing the development and progression of diabetic ocular complications. However, it is also difficult to obtain good glycemic control in many clinical cases. In this chapter, we discussed several additional medical therapeutic options for diabetic ocular complications. PKC β inhibitors and

treatments are needed to achieve a maximal effect on DR.

**3.4 Anti-VEGF agents**

option for treating DME.

**4. Comments**

ruboxistaurin (RBX) (LY333531, Eli Lilly and Co., Indianapolis, IN), administered to patients with diabetes with no or mild DR, ameliorated diabetes-induced retinal circulation time abnormalities (Aiello et al., 2006). Another multicenter, double-masked, randomized, placebo-controlled study in patients with diabetes with moderate to very severe nonproliferative diabetic retinopathy showed that RBX was well tolerated and reduced the risk of visual loss but did not prevent DR progression (PKC-DRS Study Group, 2005).

We evaluated the effect of our PKC β inhibitor (JTT-010, Takatsuki, Japan) on the development of diabetic ocular complications in SDT rats. The rats had delayed oscillatory potentials on electroretinography, but DR developed eventually. We concluded that PKC β inhibitors may require concurrent administration of antihyperglycemic drugs to achieve maximal therapeutic effects on DR (Sasase et al., 2009).

#### **3.2 Anti-AGE agents**

Previous studies have suggested the concept of "metabolic memory" associated with accumulation of AGEs as DR develops (Chibber et al., 1997; Genuth et al., 2005; Hammes et al., 1999). Another anti-AGE agent, pyridoxamine, also prevented development of DR (Stitt et al., 2002). However, clinical trials of anti-AGE agents for the treatment of DR have not yet been conducted.

Based on those reports, we evaluated the effects of oral aminoguanidine and pyridoxamine on the development of cataract and DR in SDT rats (Toyoda et al., 2011) and reported that aminoguanidine prevented accumulation of CML and resulted in almost complete inhibition of DR, but pyridoxamine did not prevent DR. Aminoguanidine seems to be a stronger inhibitor of DR than pyridoxamine.

#### **3.3 Anti-leukocyte adhesion agents**

Leukocyte adhesion to the diabetic retinal vasculature is thought to be the critical early event in the pathogenesis of DR, resulting in breakdown of the blood-retinal barrier and in capillary nonperfusion (Gurler et al., 2000; Hu et al., 1983). Adamis and coworkers (1994) reported that the antileukocyte adhesion agents, anti-intercellular adhesion molecule-1 antibody (Miyamoto et al., 1999) and anti-CD 18 antibody (Barouch et al., 2000), were useful for treating experimental DR. They also showed an antileukocyte adhesion effect using a PKC β inhibitor (Nonaka et al., 2000) and receptor for the AGEs (Kaji et al., 2007). Nagai et al. (2007) reported an inhibitory effect of an angiotensin II type 1 receptor blocker on retinal leukostasis in diabetic mice.

We tested several commercially available antileukocyte adhesion agents in diabetic rats. We first evaluated the effectiveness of the sulphonylurea gliclazide for decreasing the adhesion of neutrophils to endothelial cells and leukocyte entrapment in the retinal microcirculation of streptozotocin (STZ)-induced diabetic rats. We showed that gliclazide attenuated retinal leukostasis irrespective of hyperglycemia in diabetic rats, whereas another sulphonylurea, glibenclamide, did not. This indicated that gliclazide, among the sulphonylurea drugs, might be selectively beneficial for preventing development of DR (Kinoshita et al., 2002). We also evaluated the effectiveness of topical nipradilol, a topical antiglaucoma αβ-blocker and nitric oxide donor, on retinal microvascular leukocyte adhesion in diabetic rats. Topical nipradilol significantly reduced retinal leukostasis in the retinal microcirculation of STZinduced diabetic rats, and we think that nipradilol may be a prophylactic agent that can inhibit development of early DR through its nitric oxide donor effects on the microcirculation. We believe that most antileukocyte adhesion agents can slow progression of DR but do not inhibit it completely. Good glycemic control or other additional medical treatments are needed to achieve a maximal effect on DR.

#### **3.4 Anti-VEGF agents**

296 Diabetic Retinopathy

ruboxistaurin (RBX) (LY333531, Eli Lilly and Co., Indianapolis, IN), administered to patients with diabetes with no or mild DR, ameliorated diabetes-induced retinal circulation time abnormalities (Aiello et al., 2006). Another multicenter, double-masked, randomized, placebo-controlled study in patients with diabetes with moderate to very severe nonproliferative diabetic retinopathy showed that RBX was well tolerated and reduced the risk of visual loss but did not prevent DR progression (PKC-DRS Study Group, 2005).

We evaluated the effect of our PKC β inhibitor (JTT-010, Takatsuki, Japan) on the development of diabetic ocular complications in SDT rats. The rats had delayed oscillatory potentials on electroretinography, but DR developed eventually. We concluded that PKC β inhibitors may require concurrent administration of antihyperglycemic drugs to achieve

Previous studies have suggested the concept of "metabolic memory" associated with accumulation of AGEs as DR develops (Chibber et al., 1997; Genuth et al., 2005; Hammes et al., 1999). Another anti-AGE agent, pyridoxamine, also prevented development of DR (Stitt et al., 2002). However, clinical trials of anti-AGE agents for the treatment of DR have not yet

Based on those reports, we evaluated the effects of oral aminoguanidine and pyridoxamine on the development of cataract and DR in SDT rats (Toyoda et al., 2011) and reported that aminoguanidine prevented accumulation of CML and resulted in almost complete inhibition of DR, but pyridoxamine did not prevent DR. Aminoguanidine seems to be a

Leukocyte adhesion to the diabetic retinal vasculature is thought to be the critical early event in the pathogenesis of DR, resulting in breakdown of the blood-retinal barrier and in capillary nonperfusion (Gurler et al., 2000; Hu et al., 1983). Adamis and coworkers (1994) reported that the antileukocyte adhesion agents, anti-intercellular adhesion molecule-1 antibody (Miyamoto et al., 1999) and anti-CD 18 antibody (Barouch et al., 2000), were useful for treating experimental DR. They also showed an antileukocyte adhesion effect using a PKC β inhibitor (Nonaka et al., 2000) and receptor for the AGEs (Kaji et al., 2007). Nagai et al. (2007) reported an inhibitory effect of an angiotensin II type 1 receptor blocker on retinal

We tested several commercially available antileukocyte adhesion agents in diabetic rats. We first evaluated the effectiveness of the sulphonylurea gliclazide for decreasing the adhesion of neutrophils to endothelial cells and leukocyte entrapment in the retinal microcirculation of streptozotocin (STZ)-induced diabetic rats. We showed that gliclazide attenuated retinal leukostasis irrespective of hyperglycemia in diabetic rats, whereas another sulphonylurea, glibenclamide, did not. This indicated that gliclazide, among the sulphonylurea drugs, might be selectively beneficial for preventing development of DR (Kinoshita et al., 2002). We also evaluated the effectiveness of topical nipradilol, a topical antiglaucoma αβ-blocker and

maximal therapeutic effects on DR (Sasase et al., 2009).

stronger inhibitor of DR than pyridoxamine.

**3.3 Anti-leukocyte adhesion agents**

leukostasis in diabetic mice.

**3.2 Anti-AGE agents**

been conducted.

Since the VEGF levels increase as DR progresses (Adamis et al., 1994; Aiello et al., 1994; Amin et al., 1997; Lutty et al., 1996), VEGF is very important in the development and progression of DR. VEGF is also a vascular permeability factor and plays an important role in the development of diabetic macular edema (DME) (Mathews et al., 1997). Based on these observations, several anti-VEGF agents such as an anti-VEGF antibody (Adamis et al., 1996), soluble VEGF-receptor chimeric proteins (Aiello et al., 1995), and antisense phosphorothioate oligodeoxynucleotides against VEGF (Robinson et al., 1996) have been tested in an animal model of retinal neovascularization mimicking DR. The results were very promising. Based on these favorable results in animal studies, several clinical studies have been undertaken to evaluate treatment of DME using an anti-VEGF antibody. The RESOLVE Study evaluated the safety and efficacy of intravitreal ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) for treating patients with DME (Massin et al., 2010). Ranibizumab is a fully humanized monoclonal antibody fragment, which binds to multiple variants of VEGF-A, and is approved to treat age-related macular degeneration. The results indicated that intravitreal ranibizumab improves visual acuity and reduces macular thickness in DME. The Diabetic Retinopathy Clinical Research Network (DRCR.net) is evaluating and comparing several medical treatments for DME. The DRCR.net is a collaborative network formed in September 2002 that is dedicated to facilitating multicenter clinical studies of DR, DME, and associated conditions. Currently, there are more than 109 participating sites with over 320 physicians throughout the United States (http://drcrnet.jaeb.org/). The DRCR.net reported that intravitreal ranibizumab combined with laser treatment is more effective than laser treatment with or without triamcinolone. The anti-VEGF agents inhibit VEGF and increase capillary permeability. Macular edema is resolved by blocking increased capillary permeability. However, a drawback of the anti-VEGF agents is that they do not have long-term efficacy, so repeated injections are usually required. Moreover, a 2% prevalence of endophthalmitis over 12 months in the RESOLVE Study is worrisome. To minimize the number of intravitreal injections, gene therapy using a safe virus vector, such as an adeno-associated virus (Ideno et al., 2007), may be a future option for treating DME.

#### **4. Comments**

Good glycemic control is the most important factor for preventing the development and progression of diabetic ocular complications. However, it is also difficult to obtain good glycemic control in many clinical cases. In this chapter, we discussed several additional medical therapeutic options for diabetic ocular complications. PKC β inhibitors and

Prophylactic Medical Treatment of Diabetic Retinopathy 299

Akagi, Y., Kador, P.F., Kuwabara, T. & Kinoshita, J.H. (1983) Aldose reductase localization

Amin, R. H., Frank, R. N., Kennedy, A., Eliott, D., Puklin, J. E., Abrams, G. W. (1997)

*Ophthalmol Vis Sci*, Vol. 38, No. 1 (January 1997), pp. 36-47, ISSN 0146-0404 Barouch, F. C., Miyamoto, K., Allport J.R., Fujita K., Bursell, S.E., Aiello L.P., Luscinskas,

Chaturvedi, N., Sjolie, A.K., Stephenson, J.M., Abrahamian, H., Keipes M., Castellarin, A.,

Mellitus. *Lancet,* Vol. 351**,** No. 9095 (January 1998), pp. 28-31, ISSN 0140-6736 Chew, E. Y., Ambrosius, W.T., Davis, M.D., Danis, R.P., Gangaputra, S., Greven, C.M.,

Chibber, R., Molinatti, P.A., Rosatto, N., Lambourne, B. & Kohner, E.M. (1997) Toxic action

D'Amato, R., Wesolowski, E., Smith, L. E. (1993) Microscopic visualization of the retina by

Frank, R. N. (2002) Potential new medical therapies for diabetic retinopathy: protein kinase

Friedman, D. S., Ali, F. & Kourgialis, N. (2011) Diabetic retinopathy in the developing world:

Gabbay, K. H. (1973) The sorbitol pathway and the complications of diabetes. *N Engl J Med,*

Genuth, S., Sun, W., Cleary, P., Sell, D.R., Dahms, W., Malone, J., Sivitz, W. & Monnier, V.M.

Vol. 151**,** No. 2 (February 2011), pp. 192-194 e191, ISSN 1879-1891

Vol. 288**,** No. 16 (April 1973), pp. 831-836, ISSN 0028-4793

*Engl J Med,* Vol. 363**,** No. 3 (July 2010), pp. 233-244, ISSN 1533-4406

(February 1997), pp. 156-164, ISSN 0012-186X

287, No. 19, (May 2002), pp. 2563-9, ISSN 0098-7484

*Vis Sci,* Vol. 47**,** No. 1 (January 2006), pp. 86-92, ISSN 0146-0404

1983), pp. 1516-1519, ISSN 0146-0404

1153-1158, ISSN 0146-0404

9394

diabetes-induced retinal hemodynamic abnormalities in patients. *Invest Ophthalmol*

in human retinal mural cells. *Invest Ophthalmol Vis Sci,* Vol. 24**,** No. 11 (November

 Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. *Invest*

F.W. & Adamis, A.P. (2000) Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. *Invest Ophthalmol Vis Sci,* Vol. 41**,** No. 5 (April 2000), pp.

Rogulja-Pepeonik, Z. & Fuller, J.H. (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes

Hubbard, L., Esser, B.A., Lovato, J.F., Perdue, L.H., Goff, D.C., Jr., Cushman, W.C., Ginsberg, H.N., Elam, M.B., Genuth, S., Gerstein, H.C., Schubart, U. & Fine, L.J. (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. *N*

of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. *Diabetologia,* Vol. 40**,** No. 2

angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. *Microvasc Res*, Vol. 46, No. 2 (September 1993), pp. 135-42, ISSN 0026-2862 DCCT (2002) Effect of intensive diabetes treatment on the microvascular complications of

type 1 diabetes mellites. The Diabetes Control and Complications Trial. *JAMA*, vol

C inhibitors. *Am J Ophthalmol,* Vol. 133**,** No. 5 (May 2002), pp. 693-698, ISSN 0002-

how to approach identifying and treating underserved populations. *Am J Ophthalmol,*

(2005) Glycation and carboxymethyl lysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications trial and epidemiology of diabetes interventions and

antileukocyte adhesion agents might help prevent DR, but neither was sufficient without good concurrent glycemic control or other additional medical treatments. Anti-VEGF agents have a strong therapeutic effect in DME; however, they do not have long-term efficacy and the possibility of complications, such as endophthalmitis, associated with injection of anti-VEGF agents into the vitreous is a concern. Thus, anti-VEGF agents do not seem to be safe therapeutic options for preventing diabetic ocular complications. Oral anti-AGE agents seem to be good prophylactic medical treatments for DR in experimental animal studies. Clinical trials of oral anti-AGE agents for treating DR are worthwhile. Among the several prophylactic medical treatments for DR, we focused on the ARIs in this chapter. Epalrestat, which is commercially available in Japan, has been widely used to treat diabetic neuropathy. Although the effect of eparlestat on DR has not been clearly recognized in a clinical trial, the safety and clinical effects of long-term oral administration of the drug for treating diabetic neuropathy have been established. Thus, we believe that our findings suggest the potential therapeutic usefulness of a new ARI, ranirestat, for preventing DR. Importantly, it appears that ranirestat might prevent DR even without strict glycemic control. We look forward to the development and evaluation of new ARIs with minimal side effects for use in future clinical studies to prevent DR.

#### **5. References**

antileukocyte adhesion agents might help prevent DR, but neither was sufficient without good concurrent glycemic control or other additional medical treatments. Anti-VEGF agents have a strong therapeutic effect in DME; however, they do not have long-term efficacy and the possibility of complications, such as endophthalmitis, associated with injection of anti-VEGF agents into the vitreous is a concern. Thus, anti-VEGF agents do not seem to be safe therapeutic options for preventing diabetic ocular complications. Oral anti-AGE agents seem to be good prophylactic medical treatments for DR in experimental animal studies. Clinical trials of oral anti-AGE agents for treating DR are worthwhile. Among the several prophylactic medical treatments for DR, we focused on the ARIs in this chapter. Epalrestat, which is commercially available in Japan, has been widely used to treat diabetic neuropathy. Although the effect of eparlestat on DR has not been clearly recognized in a clinical trial, the safety and clinical effects of long-term oral administration of the drug for treating diabetic neuropathy have been established. Thus, we believe that our findings suggest the potential therapeutic usefulness of a new ARI, ranirestat, for preventing DR. Importantly, it appears that ranirestat might prevent DR even without strict glycemic control. We look forward to the development and evaluation of new ARIs with minimal side effects for use in future

Adamis, A. P., Miller, J.W., Bernal, M.T., D'Amico, D.J., Folkman J., Yeo T.K. & K. Yeo T.

Adamis, A. P., Shima, D.T., Tolentino, M.J., Gragoudas, E.S., Ferrara, N., Folkman J.,

Aiello, L. P., Avery R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S. T., Pasquale, L.R.,

Aiello, L. P., Pierce, E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King, G.L. &

Aiello, L. P., Bursell, S. E., Clermont, A., Duh, E., Ishii, H., Takagi, C., Mori, F., Ciulla, T. A.,

Aiello, L. P., Clermont A., Arora V., Davis, M.D., Sheetz, M.J. & Bursell, S.E. (2006) Inhibition

No. 9 (September 1997), pp.1473-80, ISSN 0012-1797

(1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J Ophthalmol,* Vol. 118**,** No. 4 (October

D'Amore, P.A. & Miller J.W. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. *Arch Ophthalmol,* Vol. 114**,** No. 1 (January 1996), pp. 66-71, ISSN 0003-

Thieme, H., Iwamoto, M.A., Park, J.E. et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med,* Vol. 331**,** No. 22 (December 1994), pp. 1480-1487, ISSN

Smith L.E. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. *Proc Natl Acad Sci U S A,* Vol. 92**,** No. 23 (November 1995), pp. 10457-

Ways, K., Jirousek, M., Smith, L. E., King, G. L. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. *Diabetes*, Vol. 46,

of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates

clinical studies to prevent DR.

1994), pp. 445-450, ISSN 0002-9394

**5. References**

9950

0028-4793

10461, ISSN 0027-8424

diabetes-induced retinal hemodynamic abnormalities in patients. *Invest Ophthalmol Vis Sci,* Vol. 47**,** No. 1 (January 2006), pp. 86-92, ISSN 0146-0404

Prophylactic Medical Treatment of Diabetic Retinopathy 301

Keech, A. C., Mitchell, P., Summanen, P.A., O'Day, J., Davis, T.M., Moffitt, M.S., Taskinen,

Kern, T. S. & Engerman, R.L. (1981) Distribution of aldose reductase in ocular tissues. *Exp*

Kinoshita, N., Kakehashi, A., Inoda, S., Itou, Y., Kuroki, M., Yasu, T., Kawakami, M. &

Liang, H. R., Takagaki, T., Foltz, R.L. & Bennett, P. (2005) Quantitative determination of

Massin, P., Bandello, F., Garweg, J.G., Hansen, L.L., Harding, S.P., Larsen, M., Mitchell, P.,

Mathews, M. K., Merges, C., McLeod, D.S. & Lutty, G.A. (1997) Vascular endothelial

McLeod, D. S., Lefer, D.J., Merges, C. & Lutty, G.A. (1995) Enhanced expression of

Miyamoto, K., Ogura, Y., Hamada, M., Nishiwaki, H., Hiroshiba, N. & Honda, Y. (1996) In

Miyamoto, K., Khosrof, S., Bursell, S.E. , Rohan, R., Murata, T., Clermont, A.C., Aiello, L.P.,

*Eye Res,* Vol. 33**,** No. 2 (August 1981), pp. 175-182, ISSN 0014-4835

(May 2002), pp. 735-739, ISSN 0012-186X

No. 8 (August 1996), pp. 971-977, ISSN 0003-9950

2011), pp. 101-107

1474-547X

5548

9440

0146-0404

ISSN 0146-0404

diabetic Torii rats. *The Open Diabetes Journal,* Vol. 4, Special issue 2011 (April

M.R., Simes, R.J., Tse, D., Williamson, E., Merrifield, A., Laatikainen, L.T., d'Emden, M.C., Crimet, D.C., O'Connell, R.L. & Colman, P.G. (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet,* Vol. 370**,** No. 9600 (November 2007), pp. 1687-1697, ISSN

Kanazawa, Y. (2002) Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. *Diabetologia,* Vol. 45**,** No. 5

endogenous sorbitol and fructose in human erythrocytes by atmospheric-pressure chemical ionization LC tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci,* Vol. 824**,** No. 1-2 (September 2005), pp. 36-44, ISSN 1570-0232 Lorenzi, M. (2007) The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. *Exp Diabetes Res,* Vol. 2007, pp. 61038, ISSN 1687-5303 Lutty, G. A., McLeod, D.S., Merges, C., Diggs, A. & Plouet, J. (1996) Localization of vascular

endothelial growth factor in human retina and choroid. *Arch Ophthalmol,* Vol. 114**,**

Sharp, D., Wolf-Schnurrbusch, U.E., Gekkieva, M., Weichselberger, A. & Wolf, S. (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. *Diabetes Care,* Vol. 33**,** No. 11 (November 2010), pp. 2399-2405, ISSN 1935-

growth factor and vascular permeability changes in human diabetic retinopathy. *Invest Ophthalmol Vis Sci,* Vol. 38**,** No. 13 (December 1997), pp. 2729-2741, ISSN

intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. *Am J Pathol,* Vol. 147**,** No. 3 (September 1995), pp. 642-653, ISSN 0002-

vivo quantification of leukocyte behavior in the retina during endotoxin-induced uveitis. *Invest Ophthalmol Vis Sci,* Vol. 37**,** No. 13 (December 1996), pp. 2708-2715,

Ogura, Y. & Adamis, A.P. (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1

complications participants with type 1 diabetes. *Diabetes,* Vol. 54**,** No. 11 (November 2005), pp. 3103-3111, ISSN 0012-1797

Gurler, B., Vural, H., Yilmaz, N., Oguz, H., Satici, A. & Aksoy, N. (2000) The role of

Hammes, H. P., Alt, A., Niwa, T., Clausen, J.T., Bretzel, R.G., Brownlee, M. & Schleicher,

Hirata, C., Nakano, K., Nakamura, N., Kitagawa, Y., Shigeta, H., Hasegawa, G., Ogata, M.,

Hu, T. S., Datiles, M. & Kinoshita, J.H. (1983) Reversal of galactose cataract with sorbinil in

Ideno, J., Mizukami, H., Kakehashi, A., Saito, Y., Okada, T., Urabe, M., Kume, A., Kuroki,

Kaji, Y., Usui, T., Ishida, S., Yamashiro, K., Moore, T. C., Moore, J., Yamamoto, Y.,

Kakehashi, A., Saito, Y., Mori, K., Sugi, N., Ono, R., Yamagami, H., Shinohara, M. Tamemoto,

Kakehashi, A., Inoda, S., Mameuda, C., Kuroki, M., Jono, T., Nagai, R., Horiuchi, S.,

Kakehashi, A. (2011a) Diabetic ocular complications in the SDT Rat. *The Open Diabetes Journal,* Vol. 4**,** No. Special issue 2011 (April 2011), pp. 37-40, 1876-5246. Kakekashi, A. (2011b) Nobel animal model of diabetic complications: SDT rat. *The Open*

Kakehashi, A., Takezawa, M., Toyoda, F., Kinoshita, N., Kambara, C., Yamagami, H.,

*Pract,* Vol. 79**,** No. 3 (March 2008), pp. 438-445, ISSN 1872-8227

*Diabetes Journal,* Vol. 4**,** No. Special issue 2011(April 2011), p. 14

(November 2005), pp. 3103-3111, ISSN 0012-1797

236**,** No. 3 (July 1997), pp. 712-715, ISSN 0006-291X

9 (November 1991), pp. 860-865, ISSN 0742-3071

735, ISSN 0950-222X

ISSN 0012-186X

ISSN 0146-0404

2006), pp. 455-461, ISSN 1520-7552

0404

complications participants with type 1 diabetes. *Diabetes,* Vol. 54**,** No. 11

oxidative stress in diabetic retinopathy. *Eye,* Vol. 14, Pt 5 (October 2000), pp. 730-

E.D. (1999) Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. *Diabetologia,* Vol. 42**,** No. 6 (June 1999), pp. 728-736,

Ikeda, T., Sawa, H., Nakamura, K., Ienaga, K., Obayashi, H. & Kondo, M. (1997) Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. *Biochemical and Biophysical Research Communications,* Vol.

rats. *Invest Ophthalmol Vis Sci,* Vol. 24**,** No. 5 (May 1983), pp. 640-644, ISSN 0146-

M., Kawakami, M., Ishibashi, S. & Ozawa, K. (2007) Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. *Int J Mol Med,* Vol. 19**,** No. 1 (January 2007), pp. 75-79, ISSN 1107-3756 Jennings, P. E., McLaren, M., Scott, N.A., Saniabadi, A.R. & Belch, J.J. (1991) The relationship

of oxidative stress to thrombotic tendency in type 1 diabetic patients with retinopathy. *Diabetic Medicine: a Journal of the British Diabetic Association,* Vol. 8**,** No.

Yamamoto, H., Adamis, A. P. (2007) Inhibition of diabetic leukostasis and bloodretinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. *Invest Ophthalmol Vis Sci,* Vol. 48. No. 2 (February 2007), pp. 858-65,

H., Ishikawa, S.E., Kawakami, M. & Kanazawa, Y. (2006) Characteristics of diabetic retinopathy in SDT rats. *Diabetes Metab Res Rev,* Vol. 22**,** No. 6 (November-December

Kawakami, M. & Kanazawa, Y. (2008) Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. *Diabetes Res Clin*

Kato, N., Ishikawa, S., Kawakami, M. & Kanazawa, Y. (2011) Aldose reductase inhibitor fidarestat prevents diabetic ocular complications in spontaneously diabetic Torii rats. *The Open Diabetes Journal,* Vol. 4, Special issue 2011 (April 2011), pp. 101-107

Prophylactic Medical Treatment of Diabetic Retinopathy 303

Robinson, W. G., Jr., Laver, N.M., Jacot, J.L., Glover, J.P., Basso, M.D., Blouin, P. & Hohman,

Sasase, T., Morinaga, H., Abe, T., Miyajima, K., Ohta, T., Shinohara, M., Matsushita, M.,

Schroder, S., Palinski, W. & Schmid-Schonbein, G.W. (1991) Activated monocytes and

Shinohara, M., Masuyama, T., Shoda, T, Takahashi, T., Katsuda, Y., Komeda, K., Kuroki, M.,

Stitt, A., Gardiner, T.A., Alderson, N.L., Canning, P., Frizzell, N., Duffy, N., Boyle, C.,

Sun, W., Oates, P.J., Coutcher, J.B., Gerhardinger, C. & Lorenzi, M. (2006) A selective aldose

Toyoda, F., Kakehashi, A., Ota, A., Kinoshita, N., Kambara, C., Yamagami, H., Tamemoto,

UK Prospective Diabetes Study Group. (1998a) Efficacy of atenolol and captopril in reducing

39. *BMJ,* Vol. 317**,** No. 7160 (September 1998), pp. 713-720, ISSN 0959-8138

No. 2 (February 2001), pp. 156-163, ISSN 0012-186X

*Journal,* Vol. 4**,** No. Special issue (April 2011), pp. 108-113

(October 2006), pp. 2757-2762, ISSN 0012-1797

0404

1149-1156, ISSN 0146-0404

pp.1084-7. ISSN 1462-8902

793, ISSN 0002-9513

pp. 89-100, ISSN 1560-4284

*Ophthalmol Vis Sci,* Vol. 30**,** No. 11 (November 1989), pp. 2293-2299, ISSN 0146-

T.C. (1996) Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. *Invest Ophthalmol Vis Sci,* Vol. 37**,** No. 6 (May 1996), pp.

Kakehashi, A. (2009) Protein kinase C beta inhibitor prevents diabetic peripheral neuropathy, but not histopathological abnormalities of retina in Spontaneously Diabetic Torii rat. *Diabetes, Obesity & Metabolism*, Vol. 11, No. 11 (November 2009),

granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. *Am J Pathol,* Vol. 139**,** No. 1 (July 1991), pp. 81-100, ISSN 0002-9440 Shiba, T., Inoguchi, T., Sportsman, J.R., Heath, W.F., Bursell, S. & King, G.L. (1993)

Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. *Am J Physiol,* Vol. 265**,** No. 5, Pt 1 (November 1993), pp. E783-

Kakehashi, A. & Kanazawa, Y. (2000) A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. *Int J Exp Diabetes Res,* Vol. 1, No. 2,

Januszewski, A.S., Chachich, M., Baynes, J.W. & Thorpe, S.R. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. *Diabetes,* Vol. 51**,** No. 9 (September 2002), pp. 2826-2832, ISSN 0012-1797 Stratton, I. M., Kohner, E.M., Aldington, S.J., Turner, R.C., Holman, R.R., Manley, S.E. &

Matthews, D.R. (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia,* Vol. 44**,**

reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. *Diabetes,* Vol. 55**,** No. 10

H., Ueba, H., Dobashi, Y., Ishikawa, S., Kawakami, M. & Kanazawa, Y. (2011) Prevention of proliferative diabetic retinopathy and cataract in SDT rats with aminoguanidine, an anti-advanced glycation end product agent. *The Open Diabetes*

risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS

inhibition. *Proc Natl Acad Sci U S A,* Vol. 96**,** No. 19 (September 1999), pp. 10836- 10841, ISSN 0027-8424

Nagai, N., Izumi-Nagai, K., Oike, Y., Koto, T., Satofuka, S., Ozawa, Y., Yamashiro, K., Inoue,

Nonaka, A., Kiryu, J., Tsujikawa, A, Yamashiro, K., Miyamoto, K., Nishiwaki, H., Honda, Y.

Obrosova, I. G., Pacher, P., Szabo, C., Zsengeller, Z., Hirooka, H., Stevens, M.J. & Yorek, M.A.

Okuda, J., Yashima, K., Inagaki, K. & Miwa, I. (1985) Effects of an aldose reductase inhibitor,

Pan, H. Z., Zhang, H., Chang, D., Li, H. & Sui, H. (2008) The change of oxidative stress

Pinto, C. C., Silva, K.C., Biswas, S.K., Martins, N., De Faria, J.B. & De Faria, J.M. (2007)

Reichard, P., Nilsson, B.Y. & Rosenqvist, U. (1993) The effect of long-term intensified insulin

Robison, W. G., Jr., Kador, P.F. & Kinoshita, J.H. (1983) Retinal capillaries: basement

*Science,* Vol. 221**,** No. 4616 (September 1983), pp. 1177-1179, ISSN 0036-8075 Robison, W. G., Jr., Nagata, M. & Kinoshita, J.H. (1988) Aldose reductase and retinal

Robison, W. G., Jr., Nagata, M., Tillis, T.N., Laver, N. & Kinoshita, J.H. (1989) Aldose

*N Engl J Med,* Vol. 329**,** No. 5 (July 29, 1993), pp. 304-309, ISSN 0028-4793 Robinson, G. S., Pierce, E. A., Rook, S. L., Foley, E., Webb, R., Smith, L. E. (1996)

*Radic Res,* Vol. 41**,** No. 10 (October 2007), pp. 1151-1158, ISSN 1071-5762 PKC-DRS Study Group (2005) The effect of ruboxistaurin on visual loss in patients with

*Diabetes,* Vol. 54**,** No. 1 (January 2005), pp. 234-242, ISSN 0012-1797

9 (September 2007), pp. 4342-4350, ISSN 0146-0404

(August 2000), pp. 2702-2706, ISSN 0146-0404

4 (April 2008), pp. 548-551, ISSN 1468-2079

10841, ISSN 0027-8424

2995, ISSN 0009-2363 .

2188-97, ISSN 0012-1797

4851-6, ISSN 0027-8424

pp. 343-348, ISSN 0014-4835

inhibition. *Proc Natl Acad Sci U S A,* Vol. 96**,** No. 19 (September 1999), pp. 10836-

M., Tsubota, K., Umezawa, K. & Shida, S. (2007) Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. *Invest Ophthalmol Vis Sci,* Vol. 48**,** No.

& Ogura, Y. (2000) PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. *Invest Ophthalmol Vis Sci,* Vol. 41**,** No. 9

(2005) Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.

1-[(p-bromophenyl)-sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats. *Chem Pharm Bull,* Vol. 33**,** No. 7 (July 1985), pp. 2990-

products in diabetes mellitus and diabetic retinopathy. *Br J Ophthalmol,* Vol. 92**,** No.

Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy. *Free*

moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. *Diabetes,* Vol. 54, No. 7 (July 2005), pp.

treatment on the development of microvascular complications of diabetes mellitus.

Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. *Proc Natl Acad Sci U S A,* Vol. 93, No. 10 (May 1996), pp.

membrane thickening by galactosemia prevented with aldose reductase inhibitor.

capillary basement membrane thickening. *Exp Eye Res,* Vol. 46**,** No. 3 (March 1988),

reductase and pericyte-endothelial cell contacts in retina and optic nerve. *Invest*

*Ophthalmol Vis Sci,* Vol. 30**,** No. 11 (November 1989), pp. 2293-2299, ISSN 0146- 0404

**16**

Oldřich Farsa

*Czech Republic*

**Calcium Dobesilate in Prevention**

 **and Treatment of Diabetic Retinopathy**

*Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno*

Diabetic retinopathy is a leading cause of adult vision loss and blindness. Angioprotective drugs are one of possibilities, which can be used in treatment of diabetic retinopathy. Nearly all of them are very efficient antioxidants or reactive oxygen and nitrogen species (RONS) scavengers. They often contain phenolic groups. Most of them are glycosides of plant origin with aglycones of flavonoid structure, i.e. aglycones are polyhydroxylated derivatives of 2 phenyl-4*H-*chromen-2-one or 2-phenyl-4*H-*1-benzopyran-4-one. Quercetin, which is the aglycone of many glycosides including rutoside, can serve as a typical example. Other glycosides, such as a saponoside escine (Reparil®) isolated from seeds of horse chestnut *Aesculus hippocastaneum*, have triterpenic aglycones. (In fact, escin is a mixture of several related compounds. The particular structure on the Figure I express escin I that is a mixture of two geometric isomers. They differ in *E* or *Z* configuration of 2-methylbut-2-enoyl, which is attached to originally hydroxyl oxygen in position 21 of the triterpenoid scaffold.) (Kim et al., 2004, Carrasco Vidrio, 2007). Flavonoid glycosides have poor bioavailability that is due to their low lipophilicity. This problem has been solved by etherification of phenolic groups of flavonoid aglycones with hydroxyalkyl such as hydroxyethyl groups (troxerutin) in past (Agolini Cavallini, 1987, Wadworth Faulds, 1992) Troxerutin was demonstrated to attenuate neovascularization in retinopathy in streptozocin-induced diabetic rats (Chung et al., 2005). More recently, increased bioavailability of flavonoid glycosides is reached by micronisation without changing their chemical structures. Preparations such as Detralex® or Daflon® contain standardized and micronized flavonoid fraction characterized by its content of diosmin, which is their main active constituent. Their activity in the treatment of diabetic retinopathy was clearly demonstrated (Lacombe et al., 1989). There is nearly only one exception among these quite complex compounds: calcium dobesilate (Danium ®, Doxium ®, Dexium®), which is a very simple synthetic molecule: calcium 2,5-

Calcium dobesilate is also almost the only one angioprotective drug that recently remains the object of interest in treatment of diabetic retinopathy including clinical studies (Leal et al. 2010, Einarsdottir & Stefansson, 2009, Ribeiro et al., 2006), and even it was used as a standard for determination of the particular activity of a traditional Chinese herbal medicine

**1. Introduction**

dihydroxybenzenesulfonate (see Figure 1)

preparation (Luo et al. 2009).

### **Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy**

Oldřich Farsa

*Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno Czech Republic*

#### **1. Introduction**

304 Diabetic Retinopathy

UK Prospective Diabetes Study Group. (1998b) Tight blood pressure control and risk of

*BMJ,* Vol. 317**,** No. 7160 (September 1998), pp. 703-713, ISSN 0959-8138 Yeh, L. A., Rafford, C.E., Beyer, T.A. & Hutson, N.J. (1986) Effects of the aldose reductase

Suppl 1 (April 1986), pp. 4-9, ISSN 0026-0495

macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.

inhibitor sorbinil on the isolated cultured rat lens. *Metab Clin Exp,* Vol. 35**,** No. 4

Diabetic retinopathy is a leading cause of adult vision loss and blindness. Angioprotective drugs are one of possibilities, which can be used in treatment of diabetic retinopathy. Nearly all of them are very efficient antioxidants or reactive oxygen and nitrogen species (RONS) scavengers. They often contain phenolic groups. Most of them are glycosides of plant origin with aglycones of flavonoid structure, i.e. aglycones are polyhydroxylated derivatives of 2 phenyl-4*H-*chromen-2-one or 2-phenyl-4*H-*1-benzopyran-4-one. Quercetin, which is the aglycone of many glycosides including rutoside, can serve as a typical example. Other glycosides, such as a saponoside escine (Reparil®) isolated from seeds of horse chestnut *Aesculus hippocastaneum*, have triterpenic aglycones. (In fact, escin is a mixture of several related compounds. The particular structure on the Figure I express escin I that is a mixture of two geometric isomers. They differ in *E* or *Z* configuration of 2-methylbut-2-enoyl, which is attached to originally hydroxyl oxygen in position 21 of the triterpenoid scaffold.) (Kim et al., 2004, Carrasco Vidrio, 2007). Flavonoid glycosides have poor bioavailability that is due to their low lipophilicity. This problem has been solved by etherification of phenolic groups of flavonoid aglycones with hydroxyalkyl such as hydroxyethyl groups (troxerutin) in past (Agolini Cavallini, 1987, Wadworth Faulds, 1992) Troxerutin was demonstrated to attenuate neovascularization in retinopathy in streptozocin-induced diabetic rats (Chung et al., 2005). More recently, increased bioavailability of flavonoid glycosides is reached by micronisation without changing their chemical structures. Preparations such as Detralex® or Daflon® contain standardized and micronized flavonoid fraction characterized by its content of diosmin, which is their main active constituent. Their activity in the treatment of diabetic retinopathy was clearly demonstrated (Lacombe et al., 1989). There is nearly only one exception among these quite complex compounds: calcium dobesilate (Danium ®, Doxium ®, Dexium®), which is a very simple synthetic molecule: calcium 2,5 dihydroxybenzenesulfonate (see Figure 1)

Calcium dobesilate is also almost the only one angioprotective drug that recently remains the object of interest in treatment of diabetic retinopathy including clinical studies (Leal et al. 2010, Einarsdottir & Stefansson, 2009, Ribeiro et al., 2006), and even it was used as a standard for determination of the particular activity of a traditional Chinese herbal medicine preparation (Luo et al. 2009).

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 307

The first synthesis of 2,5-dihydroxybenzenesulfonic acid that can be found is that in the article of Seyda (Seyda, 1883). On principle it was sulfonation of hydroquinone with diluted sulfuric acid in mild conditions, the reaction temperature did not exceed 50°C, for 3 hours. During this period, starting hydroquinone gradually dissolved in diluted sulfuric acid. After cooling of the solution for 24 hours, formed crystals of 2,5-dihydroxybenzenesulfonic acid were filtered off. The filtrate was diluted with water and under boiling saturated with barium carbonate. The excessive barium carbonate was then together with formed barium sulfate filtered off. The filtrate was being concentrated *in vacuo* until a white crystalline syrupy mass was formed. This viscous liquid was then poured on a porous ceramic plate to be dried. Thus barium 2,5 dihydroxybenzenesulfonate was yielded. Potassium 2,5-dihydroxybenzenesulfonate was prepared by adding of potassium carbonate into an aqueous solution of barium 2,5 dihydroxybenzenesulfonate followed by filtering-off of formed barium carbonate and concentration of the filtrate *in vacuo* into a viscous liquid that was then diluted with double volume of absolute ethanol. A brown precipitate, which had been formed was then filtered off and all the ethanol was distilled off from the filtrate with exclusion of air. Crystalline mass formed from the filtrate was then recrystallized from water to give transparent octaedric crystals. Sodium 2,5-dihydroxybenzenesulfonate was prepared similarly by adding of sodium carbonate into a solution of the barium salt. It was formed in the concentrated aqueous solution as a mass consisted from microscopic octaedric crystals. Lead 2,5 dihydroxybenzesulfonate was prepared from the crude 2,5-dihydroxybenzenesulfonic acid and lead carbonate. It precipitated from a concentrated aqueous solution as an amorphous solid that was no more soluble in water. However, it was soluble in concentrated acetic acid. The lead salt gave the free 2,5-dihydroxybenzenesulfonic acid by reaction with sulfane (see

**2. Calcium dobesilate: Chemical, historical and bibliographical data**

**2.1 Early syntheses of 2,5-dihydroxybenzenesulfonic acid and its salts**

Figure 2).

 Early syntheses of 2,5-dihydroxybenzenesulfonic acid and some its metallic salts.

Estéve-Subirana (Estéve-Subirana, 1970) has developed a different synthesis of calcium dobesilate, which is also simple and suitable for the industrial production of it. It consists of only one reaction of calcium hydrogensulfite with 1,4-benzoquinone. Such a procedure could be classified as a "redox substitution" due to changes of the oxidation states of both sulfur atom and benzene ring. However, such a synthesis is not suitable for low scale

**2.2 Industrial "redox" one-pot synthesis of calcium dobesilate vs. sulfonation**

Pb2+

S O <sup>O</sup> <sup>O</sup>-

Me = Na, K

2

Ba2+

ZnSO4 -BaSO4

Me2CO3 -Ba2CO3 OH OH

OH OH

S O <sup>O</sup> <sup>O</sup>- <sup>2</sup>

S O <sup>O</sup> <sup>O</sup>-

2

Zn2+

2Me<sup>+</sup>

Fig. 1. Calcium dobesilate as the simplest structure among angioprotective drugs.

 Calcium dobesilate as the simplest structure among angioprotective drugs.

 Calcium dobesilate: Chemical, historical and bibliographical data**

#### **2.1 Early syntheses of 2,5-dihydroxybenzenesulfonic acid and its salts**

The first synthesis of 2,5-dihydroxybenzenesulfonic acid that can be found is that in the article of Seyda (Seyda, 1883). On principle it was sulfonation of hydroquinone with diluted sulfuric acid in mild conditions, the reaction temperature did not exceed 50°C, for 3 hours. During this period, starting hydroquinone gradually dissolved in diluted sulfuric acid. After cooling of the solution for 24 hours, formed crystals of 2,5-dihydroxybenzenesulfonic acid were filtered off. The filtrate was diluted with water and under boiling saturated with barium carbonate. The excessive barium carbonate was then together with formed barium sulfate filtered off. The filtrate was being concentrated *in vacuo* until a white crystalline syrupy mass was formed. This viscous liquid was then poured on a porous ceramic plate to be dried. Thus barium 2,5 dihydroxybenzenesulfonate was yielded. Potassium 2,5-dihydroxybenzenesulfonate was prepared by adding of potassium carbonate into an aqueous solution of barium 2,5 dihydroxybenzenesulfonate followed by filtering-off of formed barium carbonate and concentration of the filtrate *in vacuo* into a viscous liquid that was then diluted with double volume of absolute ethanol. A brown precipitate, which had been formed was then filtered off and all the ethanol was distilled off from the filtrate with exclusion of air. Crystalline mass formed from the filtrate was then recrystallized from water to give transparent octaedric crystals. Sodium 2,5-dihydroxybenzenesulfonate was prepared similarly by adding of sodium carbonate into a solution of the barium salt. It was formed in the concentrated aqueous solution as a mass consisted from microscopic octaedric crystals. Lead 2,5 dihydroxybenzesulfonate was prepared from the crude 2,5-dihydroxybenzenesulfonic acid and lead carbonate. It precipitated from a concentrated aqueous solution as an amorphous solid that was no more soluble in water. However, it was soluble in concentrated acetic acid. The lead salt gave the free 2,5-dihydroxybenzenesulfonic acid by reaction with sulfane (see Figure 2).

Fig 2. Early syntheses of 2,5-dihydroxybenzenesulfonic acid and some its metallic salts.

#### **2.2 Industrial "redox" one-pot synthesis of calcium dobesilate vs. sulfonation followed by neutralization**

Estéve-Subirana (Estéve-Subirana, 1970) has developed a different synthesis of calcium dobesilate, which is also simple and suitable for the industrial production of it. It consists of only one reaction of calcium hydrogensulfite with 1,4-benzoquinone. Such a procedure could be classified as a "redox substitution" due to changes of the oxidation states of both sulfur atom and benzene ring. However, such a synthesis is not suitable for low scale

2

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 309

CaCO3

OH

S O

O

O-

2

Ca2+

OH

OH

S O

O

Fig. 4. Preparation of calcium dobesilate proposed for practical courses in chemical

**2.3 Spectral data and other important physico-chemical properties of calcium**

Infrared spectra of calcium dobesilate measured in a potassium bromide tablet contained significant absorption bands at wawenumbers 3410, 1500, 1470, 1220, 1080, 880, 815 and 640 cm-1 (Estéve-Soler, 1977) A 1H nuclear magnetic resonance spectrum (1H-NMR) of calcium dobesilate recorded in deuterium oxide contained following signals (values of chemical shifts are in ppm): 7.13 (bs, 3H, aromatic hydrogens), 6.70 (s, 2H, 2 OH) and 4.75 (s, 2H, H2O). The least signal served also as the reference one. There was evident from the ratio of integral areas that the investigated sample was calcium dobesilate monohydrate (Estéve-Soler, 1977). 1H-NMR measured by the author in deuterated dimethyl sulfoxide (DMSO-D6) was a little different. It contained the following signals (chemical shifts are in ppm, coupling constants J in Hz): 9.78 (s, 1H, OH), 8.84 (s, 1H, OH), 6.80 (d, 1H, J=2.4, arom. H), 6.57 (m, 2H, arom. H), 3.37 (s, 4H, 2 H2O). The integral area of the signal assigned to water hydrogens corresponded to 4 hydrogen atoms per one dobesilate anion so that this sample was calcium dobesilate tetrahydrate (see Fig. 5). A 13C nuclear magnetic resonance spectrum (13C-NMR) of the same sample of calcium dobesilate was recorded by the author also in DMSO-D6 in attached proton test (APT) mode. This type of carbon NMR spectrum enables to differ between carbon atoms with odd and even number of hydrogen atoms attached to every particular carbon atom so that in our case to distinguish between aromatic carbons with one hydrogen and those with no hydrogen. It contained the following signals (the values of chemical shift in ppm): 148.8 (CH), 145.8 (CH), 130.6 (CH), 117.9 (CSO3-), 116, 5

Also ultraviolet spectra, which are advantageous namely for purity determination, have been known for decades. They have been recorded from various solvents such as water, methanol or aqueous hydrochloric acid. (Negritescu et al., 1979, Kračmár et al., 1988, Chen Xiao, 2008). These electronic spectra are relatively easy to obtain because of low prices of needed UV spectrophotometers in comparison with NMR or IR spectrometers. This is probably one of the reasons for which some pharmacopoeias use this method for confirmation of identity of calcium dobesilate monohydrate, which is official as a drug substance (Czech Pharmacopoeia 2009, 2009, European Pharmacopoeia Edition 7.2, 2011). In accordance with both pharmacopoeias, the UV spectrum of calcium dobesilate measured in water can have absorption maxima at 221 and 301 nm and the specific absorbance at 301 nm

OH

OH

OH

H2SO4

45 °C, 3 h

(COH), 112.8 (COH) (see Fig. 5).

in the range 174 to 181 (see Fig. 6).

OH

disciplines

**dobesilate**

preparations of calcium dobesilate including those that are performed by students in practical classes in subjects such as medicinal or organic chemistry. These practical educations can be met by students of fields such as pharmacy or chemistry at appropriate schools or faculties. The main problem of the Estéve-Subirana's procedure consists in use of calcium hydrogensulfite, which is not commercially available in solid state. Its concentrated aqueous solution is frequently prepared by reaction of gaseous sulfur dioxide with an aqueous suspension of calcium carbonate. This reaction can proceed in a special bubble column reactor typical for industrial processes such as the procedure developed by Rückauf and colleagues (Rückauf et al., 1990).

Fig. 3. Preparation of calcium dobesilate according to Estéve-Subirana (Estéve-Subirana, 1970) preceeded with preparation of calcium hydrogensulfite according to Rückauf et al. (Rückauf et al. , 1990).

To develop a simple and effective synthesis of calcium dobesilate that does not require calcium hydrogensulfite, we returned to sulfonation of hydroquinone. After we had tried several procedures using diluted sulfuric acid without significant successes (Šablatura, 2005), we came back to the original preparation of Seyda (Seyda, 1883). We modified his synthesis of barium 2,5-dihydroxybenzenesulfonate for preparation calcium dobesilate in conditions of today. Hydroquinone was sulfonated with concentrated sulfuric acid, a resulted mixture was then neutralized short boiling with calcium carbonate. Poorly soluble calcium sulfate precipitate was then filtered off. The filtrate was evaporated nearly to dryness. The residuum was disperged in concentated ethanol and filtered. The ethanolic filtrate was evaporated to dryness. Recrystallization of the residuum from the mixture butan-1-ol / chloroform gave calcium dobesilate in the form of its monohydrate (see Fig. 4).

Crystallization trials from several with various ratios alcohol / water mixtures led in most to solid solvates, e.g. calcium dobesilate : propan-2-ol 1 : 1.3 (dobesilate : alcohol ratio was estimated from 1H-NMR spectrum). Simple confirmation of identity of the product by determination of its melting point is impossible because of high value of its melting temperature, but it can be identified by simple spectrophotometry in UV region according to Czech Pharmacopoeia 2005 Edition (Czech Pharmacopoeia 2009, 2009) (see also bellow). This procedure was published in a journal devoted to chemical education (Farsa Šablatura, 2008) and in more detailed and modified form also in an instruction manual for practical courses in medicinal chemistry (Beneš Farsa, 2007). It is notable that, short time after its publishing, very similar procedures of preparation of calcium dobesilate appeared in Chinese patents (Yao 2010, Yang et al. 2010).

preparations of calcium dobesilate including those that are performed by students in practical classes in subjects such as medicinal or organic chemistry. These practical educations can be met by students of fields such as pharmacy or chemistry at appropriate schools or faculties. The main problem of the Estéve-Subirana's procedure consists in use of calcium hydrogensulfite, which is not commercially available in solid state. Its concentrated aqueous solution is frequently prepared by reaction of gaseous sulfur dioxide with an aqueous suspension of calcium carbonate. This reaction can proceed in a special bubble column reactor typical for industrial processes such as the procedure developed by Rückauf

Fig. 3. Preparation of calcium dobesilate according to Estéve-Subirana (Estéve-Subirana, 1970) preceeded with preparation of calcium hydrogensulfite according to Rückauf et al.

To develop a simple and effective synthesis of calcium dobesilate that does not require calcium hydrogensulfite, we returned to sulfonation of hydroquinone. After we had tried several procedures using diluted sulfuric acid without significant successes (Šablatura, 2005), we came back to the original preparation of Seyda (Seyda, 1883). We modified his synthesis of barium 2,5-dihydroxybenzenesulfonate for preparation calcium dobesilate in conditions of today. Hydroquinone was sulfonated with concentrated sulfuric acid, a resulted mixture was then neutralized short boiling with calcium carbonate. Poorly soluble calcium sulfate precipitate was then filtered off. The filtrate was evaporated nearly to dryness. The residuum was disperged in concentated ethanol and filtered. The ethanolic filtrate was evaporated to dryness. Recrystallization of the residuum from the mixture butan-1-ol / chloroform gave calcium dobesilate in the form of its monohydrate (see Fig. 4). Crystallization trials from several with various ratios alcohol / water mixtures led in most to solid solvates, e.g. calcium dobesilate : propan-2-ol 1 : 1.3 (dobesilate : alcohol ratio was estimated from 1H-NMR spectrum). Simple confirmation of identity of the product by determination of its melting point is impossible because of high value of its melting temperature, but it can be identified by simple spectrophotometry in UV region according to Czech Pharmacopoeia 2005 Edition (Czech Pharmacopoeia 2009, 2009) (see also bellow). This procedure was published in a journal devoted to chemical education (Farsa Šablatura, 2008) and in more detailed and modified form also in an instruction manual for practical courses in medicinal chemistry (Beneš Farsa, 2007). It is notable that, short time after its publishing, very similar procedures of preparation of calcium dobesilate appeared

OH OH

S O

<sup>O</sup> <sup>O</sup>-

2

Ca2+

and colleagues (Rückauf et al., 1990).

<sup>2</sup> <sup>O</sup> <sup>O</sup> + Ca(HSO3)2

in Chinese patents (Yao 2010, Yang et al. 2010).

(Rückauf et al. , 1990).

CaCO3 + SO2+ H2O Ca(HSO3)2 + CO2

Fig. 4. Preparation of calcium dobesilate proposed for practical courses in chemical disciplines

#### **2.3 Spectral data and other important physico-chemical properties of calcium dobesilate**

Infrared spectra of calcium dobesilate measured in a potassium bromide tablet contained significant absorption bands at wawenumbers 3410, 1500, 1470, 1220, 1080, 880, 815 and 640 cm-1 (Estéve-Soler, 1977) A 1H nuclear magnetic resonance spectrum (1H-NMR) of calcium dobesilate recorded in deuterium oxide contained following signals (values of chemical shifts are in ppm): 7.13 (bs, 3H, aromatic hydrogens), 6.70 (s, 2H, 2 OH) and 4.75 (s, 2H, H2O). The least signal served also as the reference one. There was evident from the ratio of integral areas that the investigated sample was calcium dobesilate monohydrate (Estéve-Soler, 1977). 1H-NMR measured by the author in deuterated dimethyl sulfoxide (DMSO-D6) was a little different. It contained the following signals (chemical shifts are in ppm, coupling constants J in Hz): 9.78 (s, 1H, OH), 8.84 (s, 1H, OH), 6.80 (d, 1H, J=2.4, arom. H), 6.57 (m, 2H, arom. H), 3.37 (s, 4H, 2 H2O). The integral area of the signal assigned to water hydrogens corresponded to 4 hydrogen atoms per one dobesilate anion so that this sample was calcium dobesilate tetrahydrate (see Fig. 5). A 13C nuclear magnetic resonance spectrum (13C-NMR) of the same sample of calcium dobesilate was recorded by the author also in DMSO-D6 in attached proton test (APT) mode. This type of carbon NMR spectrum enables to differ between carbon atoms with odd and even number of hydrogen atoms attached to every particular carbon atom so that in our case to distinguish between aromatic carbons with one hydrogen and those with no hydrogen. It contained the following signals (the values of chemical shift in ppm): 148.8 (CH), 145.8 (CH), 130.6 (CH), 117.9 (CSO3-), 116, 5 (COH), 112.8 (COH) (see Fig. 5).

Also ultraviolet spectra, which are advantageous namely for purity determination, have been known for decades. They have been recorded from various solvents such as water, methanol or aqueous hydrochloric acid. (Negritescu et al., 1979, Kračmár et al., 1988, Chen Xiao, 2008). These electronic spectra are relatively easy to obtain because of low prices of needed UV spectrophotometers in comparison with NMR or IR spectrometers. This is probably one of the reasons for which some pharmacopoeias use this method for confirmation of identity of calcium dobesilate monohydrate, which is official as a drug substance (Czech Pharmacopoeia 2009, 2009, European Pharmacopoeia Edition 7.2, 2011). In accordance with both pharmacopoeias, the UV spectrum of calcium dobesilate measured in water can have absorption maxima at 221 and 301 nm and the specific absorbance at 301 nm in the range 174 to 181 (see Fig. 6).

Absorbance (AU)

0

OH

OH

sulfonate.

0.2

0.4

0.6

0.8

221

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 311

200 220 240 260 280 300 320 Wavelength (nm)

Fig. 6. Ultraviolet spectrum of calcium dobesilate measured in an aqueous solution at Agilent 8453 diode array UV-VIS spectrophotometer in accordance with requirements of the

anhydrous calcium dobesilate melts above 300°C under decomposition (Milne, 2002).

can be used for purifying of the drug by recrystallization (Nováček et al., 1987).

3,6-dioxocyclohexa-1,4-diene-1-sulfonate (see Fig. 7).

O-

S

O

O

As it was mentioned above, melting point of calcium dobesilate monohydrate is out of range of measurement of common melting point apparatuses and thus it is not suitable for identification of calcium dobesilate monohydrate as a substance. Milne states that

The pharmacopoeias state that calcium dobesilate monohydrate is very soluble in water, freely soluble in anhydrous ethanol, very slightly soluble in propan-2-ol and practically insoluble in dichloromethane (Czech Pharmacopoeia 2009, 2009, European Pharmacopoeia Edition 7.2, 2011). In fact, it is extremely soluble in water: three weight parts of calcium dobesilate monohydrate dissolve in one part of boiling water. This ratio of the compound and the solvent

Since calcium dobesilate is a hydroquinone derivative it can be easily oxidized into calcium

oxidation

reduction

, - 2H+

, + 2H+

+ 2e-

Fig. 7. Reversible oxidation of dobesilate anion into 3,6-dioxocyclohexa-1,4-diene-1-

253

European Pharmacopoeia (European Pharmacopoeia Edition 7.2, 2011).

301

O

S

O

O-

O

O

Fig. 5. 1H-NMR spectrum of calcium dobesilate dihydrate recorded at 200 MHz Varian Gemini FT-NMR spectrometer in DMSO-D6 solution (top) and its 13C-NMR spectrum measured in DMSO-D6 solution at 50 MHz at the same instrument (bottom).

0

0

500

1000

100

200

300

400

500

600

2.48

3.37

3.83

ppm (t1) 9.0 8.0 7.0 6.0 5.0 4.0 3.0

6.80

1.11

117.9

116.5

1.18

ppm (t1) <sup>150</sup> <sup>100</sup> <sup>50</sup>

112.8

Fig. 5. 1H-NMR spectrum of calcium dobesilate dihydrate recorded at 200 MHz Varian Gemini FT-NMR spectrometer in DMSO-D6 solution (top) and its 13C-NMR spectrum

measured in DMSO-D6 solution at 50 MHz at the same instrument (bottom).

6.57

9.76

1.00

0.63

148.8

145.8

130.6

8.84

Fig. 6. Ultraviolet spectrum of calcium dobesilate measured in an aqueous solution at Agilent 8453 diode array UV-VIS spectrophotometer in accordance with requirements of the European Pharmacopoeia (European Pharmacopoeia Edition 7.2, 2011).

As it was mentioned above, melting point of calcium dobesilate monohydrate is out of range of measurement of common melting point apparatuses and thus it is not suitable for identification of calcium dobesilate monohydrate as a substance. Milne states that anhydrous calcium dobesilate melts above 300°C under decomposition (Milne, 2002).

The pharmacopoeias state that calcium dobesilate monohydrate is very soluble in water, freely soluble in anhydrous ethanol, very slightly soluble in propan-2-ol and practically insoluble in dichloromethane (Czech Pharmacopoeia 2009, 2009, European Pharmacopoeia Edition 7.2, 2011). In fact, it is extremely soluble in water: three weight parts of calcium dobesilate monohydrate dissolve in one part of boiling water. This ratio of the compound and the solvent can be used for purifying of the drug by recrystallization (Nováček et al., 1987).

Since calcium dobesilate is a hydroquinone derivative it can be easily oxidized into calcium 3,6-dioxocyclohexa-1,4-diene-1-sulfonate (see Fig. 7).

Fig. 7. Reversible oxidation of dobesilate anion into 3,6-dioxocyclohexa-1,4-diene-1 sulfonate.

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 313

hydroquinone. calcium dobesilate could have the retention time about 6 min in this system (European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 2009, 2009). Finally, Rona and Ary reported a reversed phase-high performance liquid chromatography procedure suitable for determination of calcium dobesilate in human plasma for purposes of bioequivalence studies. They used a C16 reverse phase modified with inserted amide moiety. Such phases have been recommended as suitable for separation of polar compounds (Sigma-Aldrich, 2011). The mixture phosphate buffer pH 2.5 : acetonitrile 3 : 1 was used as a mobile phase, the detection wavelength was 305 nm (Rona Ary, 2001). It is interesting that no high performance liquid chromatography procedure using electrochemical detection has been reported although redox properties of calcium dobesilate offer this possibility of sensitive

**2.4 Polymorphism, solvate complexes and co-crystals of calcium dobesilate**

water per 1 mol calcium dobesilate respectively have been patented (Huang, 2007).

Calcium dobesilate has been patented as an active ingredient of its mixed-phase cocrystaline form. Such co-crystals are based on a theory that the additive(s), which are also known as co-crystal formers, are co-crystallized as minor non-stoichiometric components in the active agent's crystalline matrix. This co-crystalline phase has then semi-crystalline nature and contains a high incidence of crystal defects. Any excess additive that is not cocrystallized with the active agent forms a separate phase (Additive Phase) apart from the active agent, which results in the mixed phase co-crystal composition. The Additive Phase and the active agent crystals containing co-crystallized additive can be tightly agglomerated forming a mixed phase co-crystal particle. The unique physical properties obtained by this process of preparation can include changes in apparent solubility, crystallinity, water wetability, dissolution rates, physical powder properties (e.g., bulk density, absolute density, refractive index, x-ray diffraction, spectral, flowability, hygroscopicity, adsorption, and compaction), bioavailability, apparent permeability, apparent taste, and/or stability (Goldman, 2005). Calcium dobesilate is believed to form co-crystals with co-crystal former, which has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and

Calcium dobesilate monohydrate is the most common crystalline form of calcium dobesilate and is also official in many pharmacopoeias. It is also a subject of a mild misunderstanding between some pharmacopoeias and Chemical Abstracts or their electronic version, the data base SciFinder, because the Chemical Abstracts Service reference number (CAS RN) 20123- 80-2 is in the pharmacopoeias (European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 2009, 2009) assigned to this monohydrate while in SciFinder to anhydrous calcium dobesilate. Calcium dobesilate monohydrate is then referred in SciFinder under CAS RN 117552-79-1 (SciFinder, 2011). Calcium dobesilate monohydrate has been characterized by powder X-ray diffraction spectrum (Lu, 2005) and by two methods of differential thermal analysis (DTA); thermogravimetric analysis (TGA) a differential scanning calorimetry (DSC). Caproiu and colleagues reported based on DTA that calcium dobesilate monohydrate showed dehydration starting at 115°C and ending at 180°C (Caproiu et al., 1988) while Lu stated the dehydration interval between 134°C and 180°C (Lu, 2005). Calcium dobesilate dihydrate, sesquihydrate, i.e. hydrate containing 1.5 mol water per 1 mol calcium dobesilate, and non-stoichiometric hydrates containing 5/7, 5/4, 1.6 and 2.6 mol

detection.

Reversibility of this reaction has been repeatedly demonstrated by cyclic voltammetry with various types of electrodes. (Zheng et al., 2007, Zhang Zhang, 2009, Zhang et al., 2011). Such methods have reached very low detection limit for calcium dobesilate up to 4.0 × 10-8 mol L-1 and have been resistant to interference with other reducing compounds occurring in body liquids such as uric acid, serotonin, and ascorbic acid (Hu et al., 2009). That is why they have been successfully used not only for identification and assay of calcium dobesilate in substance samples and drug formulations (Guangzhi et al., 2009) but also in biological samples (Zheng et al., 2007). The influence of bovine serum albumin (BSA) on the electrochemical behavior of calcium dobesilate was also investigated. The stoichiometric coefficient and the association constant of calcium dobesilate with BSA were obtained by this technique in addition to those obtained by UV-spectrophotometry. It was found that the peak currents in cyclic voltammetry diagrams decreased and the peak potentials stayed almost unchanged in the presence of BSA, indicating that there might exist an interaction between calcium dobesilate and BSA (Xu et al., 2009). Oxidation of calcium dobesilate is also used for its titrimetric assay by means of cerimetry with potentiometric end-point determination required by some pharmacopoeias (European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 2009, 2009). This method gives more accurate results than chelatometric titrimetry using N,N'-ethylenediaminetetraacetic acid (EDTA) for complexation of calcium ion of calcium dobesilate (Zhang Xu, 1999). The activity of calcium dobesilate as a reduction agent is also reason of its radical-scavenging activity, which plays an important role in its mechanism of action as a drug of diabetic retinopathy (see further).

The chromatographic behaviour of calcium dobesilate is determined by its extremely low lipophilicity as it is an ionic salt. Thin-layer chromatography (TLC) on a silica gel normal phase was being used for identification of hydroquinone as an impurity in calcium dobesilate substance. While hydroquinone migrates in the required mobile phase dichloromethane : methyl acetate : ethyl acetate 20 : 30 : 50, calcium dobesilate remains at the start (Czech Pharmacopoeia 2002, 2002, Šablatura, 2006). Reversed phase high performance liquid chromatography (reversed phase-high performance liquid chromatography) methods for identification and content assay of calcium dobesilate namely in various samples have been reported. Assays of calcium dobesilate in dog blood plasma for pharmacokinetic purposes after its single (Plessas et al., 1986a) and repeated (Plessas et al., 1986b) administration were performed using a C18 column. A similar method using a Hypersil® octadecylsilyl silica gel (ODS) column and UV detection in absorption maximum of calcium dobesilate at 301 nm with mobile phase methanol : water 7 : 3 and flow rate 1.0 mL min-1 has been developed for determination of calcium dobesilate in pharmaceuticals (Zhu Chen, 2005). Slightly different conditions, mobile phase acetonitrile : water buffer pH 2.5 1 : 1, flow rate 1.0 mL min-1 and detection wavelength 290 nm, were used in a procedure suitable for simultaneous determination of calcium dobesilate and lidocaine hydrochloride, dexamethasone acetate, butylhydroxyanisol and hydroquinone as a degradation product of calcium dobesilate in suppositories and an ointment. The retention times ranged between 2.4 min for the most hydrophilic calcium dobesilate to 17.1 min for the most hydrophilic BHA (Zivanovic et al., 2005). Also recent pharmacopoeias utilize reversed phase-high performance liquid chromatography using a spherical end-capped ODS column, mobile phase acetonitrile : aqueous buffer solution 1 : 9, flow rate 0.8 mL min-1 and detection wavelength 220 nm for the test for presence of impurities, namely

Reversibility of this reaction has been repeatedly demonstrated by cyclic voltammetry with various types of electrodes. (Zheng et al., 2007, Zhang Zhang, 2009, Zhang et al., 2011). Such methods have reached very low detection limit for calcium dobesilate up to 4.0 × 10-8 mol L-1 and have been resistant to interference with other reducing compounds occurring in body liquids such as uric acid, serotonin, and ascorbic acid (Hu et al., 2009). That is why they have been successfully used not only for identification and assay of calcium dobesilate in substance samples and drug formulations (Guangzhi et al., 2009) but also in biological samples (Zheng et al., 2007). The influence of bovine serum albumin (BSA) on the electrochemical behavior of calcium dobesilate was also investigated. The stoichiometric coefficient and the association constant of calcium dobesilate with BSA were obtained by this technique in addition to those obtained by UV-spectrophotometry. It was found that the peak currents in cyclic voltammetry diagrams decreased and the peak potentials stayed almost unchanged in the presence of BSA, indicating that there might exist an interaction between calcium dobesilate and BSA (Xu et al., 2009). Oxidation of calcium dobesilate is also used for its titrimetric assay by means of cerimetry with potentiometric end-point determination required by some pharmacopoeias (European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 2009, 2009). This method gives more accurate results than chelatometric titrimetry using N,N'-ethylenediaminetetraacetic acid (EDTA) for complexation of calcium ion of calcium dobesilate (Zhang Xu, 1999). The activity of calcium dobesilate as a reduction agent is also reason of its radical-scavenging activity, which plays an important role in its mechanism of action as a drug of diabetic retinopathy

The chromatographic behaviour of calcium dobesilate is determined by its extremely low lipophilicity as it is an ionic salt. Thin-layer chromatography (TLC) on a silica gel normal phase was being used for identification of hydroquinone as an impurity in calcium dobesilate substance. While hydroquinone migrates in the required mobile phase dichloromethane : methyl acetate : ethyl acetate 20 : 30 : 50, calcium dobesilate remains at the start (Czech Pharmacopoeia 2002, 2002, Šablatura, 2006). Reversed phase high performance liquid chromatography (reversed phase-high performance liquid chromatography) methods for identification and content assay of calcium dobesilate namely in various samples have been reported. Assays of calcium dobesilate in dog blood plasma for pharmacokinetic purposes after its single (Plessas et al., 1986a) and repeated (Plessas et al., 1986b) administration were performed using a C18 column. A similar method using a Hypersil® octadecylsilyl silica gel (ODS) column and UV detection in absorption maximum of calcium dobesilate at 301 nm with mobile phase methanol : water 7 : 3 and flow rate 1.0 mL min-1 has been developed for determination of calcium dobesilate in pharmaceuticals (Zhu Chen, 2005). Slightly different conditions, mobile phase acetonitrile : water buffer pH 2.5 1 : 1, flow rate 1.0 mL min-1 and detection wavelength 290 nm, were used in a procedure suitable for simultaneous determination of calcium dobesilate and lidocaine hydrochloride, dexamethasone acetate, butylhydroxyanisol and hydroquinone as a degradation product of calcium dobesilate in suppositories and an ointment. The retention times ranged between 2.4 min for the most hydrophilic calcium dobesilate to 17.1 min for the most hydrophilic BHA (Zivanovic et al., 2005). Also recent pharmacopoeias utilize reversed phase-high performance liquid chromatography using a spherical end-capped ODS column, mobile phase acetonitrile : aqueous buffer solution 1 : 9, flow rate 0.8 mL min-1 and detection wavelength 220 nm for the test for presence of impurities, namely

(see further).

hydroquinone. calcium dobesilate could have the retention time about 6 min in this system (European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 2009, 2009). Finally, Rona and Ary reported a reversed phase-high performance liquid chromatography procedure suitable for determination of calcium dobesilate in human plasma for purposes of bioequivalence studies. They used a C16 reverse phase modified with inserted amide moiety. Such phases have been recommended as suitable for separation of polar compounds (Sigma-Aldrich, 2011). The mixture phosphate buffer pH 2.5 : acetonitrile 3 : 1 was used as a mobile phase, the detection wavelength was 305 nm (Rona Ary, 2001). It is interesting that no high performance liquid chromatography procedure using electrochemical detection has been reported although redox properties of calcium dobesilate offer this possibility of sensitive detection.

#### **2.4 Polymorphism, solvate complexes and co-crystals of calcium dobesilate**

Calcium dobesilate monohydrate is the most common crystalline form of calcium dobesilate and is also official in many pharmacopoeias. It is also a subject of a mild misunderstanding between some pharmacopoeias and Chemical Abstracts or their electronic version, the data base SciFinder, because the Chemical Abstracts Service reference number (CAS RN) 20123- 80-2 is in the pharmacopoeias (European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 2009, 2009) assigned to this monohydrate while in SciFinder to anhydrous calcium dobesilate. Calcium dobesilate monohydrate is then referred in SciFinder under CAS RN 117552-79-1 (SciFinder, 2011). Calcium dobesilate monohydrate has been characterized by powder X-ray diffraction spectrum (Lu, 2005) and by two methods of differential thermal analysis (DTA); thermogravimetric analysis (TGA) a differential scanning calorimetry (DSC). Caproiu and colleagues reported based on DTA that calcium dobesilate monohydrate showed dehydration starting at 115°C and ending at 180°C (Caproiu et al., 1988) while Lu stated the dehydration interval between 134°C and 180°C (Lu, 2005). Calcium dobesilate dihydrate, sesquihydrate, i.e. hydrate containing 1.5 mol water per 1 mol calcium dobesilate, and non-stoichiometric hydrates containing 5/7, 5/4, 1.6 and 2.6 mol water per 1 mol calcium dobesilate respectively have been patented (Huang, 2007).

Calcium dobesilate has been patented as an active ingredient of its mixed-phase cocrystaline form. Such co-crystals are based on a theory that the additive(s), which are also known as co-crystal formers, are co-crystallized as minor non-stoichiometric components in the active agent's crystalline matrix. This co-crystalline phase has then semi-crystalline nature and contains a high incidence of crystal defects. Any excess additive that is not cocrystallized with the active agent forms a separate phase (Additive Phase) apart from the active agent, which results in the mixed phase co-crystal composition. The Additive Phase and the active agent crystals containing co-crystallized additive can be tightly agglomerated forming a mixed phase co-crystal particle. The unique physical properties obtained by this process of preparation can include changes in apparent solubility, crystallinity, water wetability, dissolution rates, physical powder properties (e.g., bulk density, absolute density, refractive index, x-ray diffraction, spectral, flowability, hygroscopicity, adsorption, and compaction), bioavailability, apparent permeability, apparent taste, and/or stability (Goldman, 2005). Calcium dobesilate is believed to form co-crystals with co-crystal former, which has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 315

significantly increased the activity of glutathione S-transferase (GST) after three days of treatment and also, but to a lower extent, the activity of -glutamyltransferase (-GT). Both enzymes are known to be involved in the glutathione (GSH) metabolic cycle. This enzymatic behaviour was reversed at seven days of treatment, with a significant GST decrease and a - GT activation. After seven days of calcium dobesilate exposure, the intracellular GSH content was enhanced and this resulted in a dramatic decrease in lipid peroxidation, underlining the powerful antioxidant properties of calcium dobesilate in human PBMC. (Graber et al., 1998). These results indicate that *in vitro* antioxidant effects of calcium dobesilate manifest *in vivo* by reduced lipid peroxidation and contribute to the prevention of

**3.2 Angioprotective action of calcium dobesilate against reactive oxygen species-**

**3.3 Enhancement of nitric oxide synthase activity in endothelial cells**

Microvascular permeability seems to be strongly increased by ROS generated *in situ*. In an *in vivo* experiment in rats, calcium dobesilate administered intraperitoneally (i.p.), intravenously (i.v.) and orally (p.o.) significantly reduced microvascular permeabilization induced by ROS in the rat peritoneal cavity. ROS were generated again either with the system xanthine / xanthine oxidase or with PMS/NADH. Microvascular permeabilization was quantified by Evans blue extravasation. The activity of calcium dobesilate was

The term endothelium-derived relaxing factor was originally proposed by Robert Furchgott for a then unknown factor leading to relaxation of the smooth muscle of large arteries in response to acetylcholine. Nitric oxide NO, which is in fact a free radical, was later found to be the mediator of this response. Most of NO in the body is synthesized by the endothelial isoform of NO synthase (NOS) from its precursor L-arginine (Palmer et al., 1988a), which is inhibited by false substrates of NOS, e.g., L-NG-monomethyl arginine (L-NMMA) (Palmer et al., 1988b). NOS is a highly regulated protein and the endothelial form (eNOS) is predominantly found in endothelial cells. In them, two different isoenzymes can be expressed, depending on the activation state of these cells. In resting, non-activated endothelial cells a constitutive enzyme (ecNOS) is expressed (Moncada & Higgs, 1993) and after challenge with proinflammatory cytokines and/or bacterial endotoxin a cytokineinducible enzyme (iNOS) is expressed in addition (Suschek et al., 1993). The constitutive, calcium-dependent isoenzyme produces low amounts of NO for short periods of time (Palacios et al., 1989). This endothelium-derived NO plays a crucial role in blood pressure regulation (Rees et al., 1989), in inhibition of platelet aggregation and platelet adhesion (Radomski et al., 1987a, b), and in modulating leukocyte adhesion, an essential step early in tissue inflammation (Kubes et al., 1991, Zimmerman et al., 1992). The inducible, cytosolic, calcium-independent NO synthase is expressed only after cell activation and releases large amounts of NO for longer periods of time that functions as cytotoxic and immune regulatory effector molecule (Kröncke et al., 1995). Diabetes-induced vascular function abnormalities are besides other biochemical and morphological changes also reflected by decreased synthesis of NO (Durante et al., 1988, McVeigh et al., 1992). Magnesium 2,5 dihydroxybenzenesulfonate or magnesium dobesilate was used instead of calcium

apoptosis.

**induced capillary permeability**

comparable to that of rutin (Brunet et al., 1998b).

methylsulfanyl, such that calcium dobesilate and co-crystal former are capable of cocrystallizing from a solution phase under crystallization conditions (Almarsson et al., 2011). Calcium dobesilate has also been patented as a component of an ionic liquid (Rogers et al., 2010) that can be used for overcoming of influence polymorphism in drug substances (Rogers et al., 2007). calcium dobesilate can also form solvates with propylene glycol, which could be more stable than hydrates (Tawa et al, 2010). However, none of these patents contains a particular example of processing of calcium dobesilate.

#### **3. Activities found in** *In Vitro* **and animal models**

#### **3.1 Antioxidant and antiradical activity**

Antioxidant or reduction activity of calcium dobesilate is a result of its hydroquinone structure. This was mentioned above in section 2.3 in relationship to its analytical behaviour (compare Fig. 8) but this type of reactivity has also an important impact to its biological activity. The ability of 2,5-dihydroxybenzenesulfonic acid salts to reduce mercurous and silver nitrates to metallic mercury and silver respectively was first observed by Seyda (Seyda, 1883). Calcium dobesilate was shown to actively interact with toxic superoxide anion radical O2°- .This reactive oxygen species (ROS) was generated either by UV irradiation of an aqueous solution of glycyltryptohphan at 280 nm, or by irradiation of a mixture of glycyltryptophan with riboflavine with visible light. Thus calcium dobesilate showed the activity similar to that of superoxide dismutase (Lozovskaia et al., 1990). This result was confirmed in the experiment in which superoxide radicals were generated in the system xanthine/xanthine oxidase/ferrous chloride, but potency of calcium dobesilate to scavenge superoxide radicals was 23 times less than that of rutin that was used for comparison. However, calcium dobesilate was as potent as rutin in scavenging hydroxyl radicals generated *in vitro* via the iron-catalyzed Haber-Weiss reaction from superoxide anion (IC50 = 1.1 vs 0.7 M, respectively). In human erythrocytes, calcium dobesilate reduced phenazine methosulfate dependent lipid peroxydation, although the effect was observed at high concentration (Brunet et al., 1998a). Oral treatment with calcium dobesilate significantly protected diabetic rat retina against a free radicals mediated injury induced by ischemia/reperfusion. This was observed in an *in vivo* experiment with streptozotocininduced diabetic rats (Szabo et al., 2001). The results of these experiments support the hypothesis that the antioxidant properties of calcium dobesilate could play a role in its angioprotective properties *in vivo*. The antioxidant effects of calcium dobesilate were further investigated in relation to the oxidative status, apoptosis and in vitro proliferation of human peripheral blood mononuclear cells (PBMC) isolated from healthy donors. Calcium dobesilate alone did not modify cell growth in vitro until 10 μM. This molecule counteracted oxidative damages generated by the high reducing aldose 2-deoxy-D-ribose (dR). PBMC incubated with the reducing sugars D(-)-ribose and 2-deoxy-D-ribose (dR) exhibited characteristic patterns of apoptosis, such as DNA fragmentation and morphological changes, which can be prevented by exogenous antioxidants such as N-acetyl-L-cysteine (Barbieri et al., 1994) and/or other agents (Anderson et al., 1994). Calcium dobesilate was shown to reduce apoptosis by delaying both membrane permeability changes and DNA fragmentation. Calcium dobesilate 10 μM affected in a time-dependent dynamics several parameters representative of the cellular oxidative status. In particular, calcium dobesilate

methylsulfanyl, such that calcium dobesilate and co-crystal former are capable of cocrystallizing from a solution phase under crystallization conditions (Almarsson et al., 2011). Calcium dobesilate has also been patented as a component of an ionic liquid (Rogers et al., 2010) that can be used for overcoming of influence polymorphism in drug substances (Rogers et al., 2007). calcium dobesilate can also form solvates with propylene glycol, which could be more stable than hydrates (Tawa et al, 2010). However, none of these patents

Antioxidant or reduction activity of calcium dobesilate is a result of its hydroquinone structure. This was mentioned above in section 2.3 in relationship to its analytical behaviour (compare Fig. 8) but this type of reactivity has also an important impact to its biological activity. The ability of 2,5-dihydroxybenzenesulfonic acid salts to reduce mercurous and silver nitrates to metallic mercury and silver respectively was first observed by Seyda (Seyda, 1883). Calcium dobesilate was shown to actively interact with toxic superoxide anion radical O2°-.This reactive oxygen species (ROS) was generated either by UV irradiation of an aqueous solution of glycyltryptohphan at 280 nm, or by irradiation of a mixture of glycyltryptophan with riboflavine with visible light. Thus calcium dobesilate showed the activity similar to that of superoxide dismutase (Lozovskaia et al., 1990). This result was confirmed in the experiment in which superoxide radicals were generated in the system xanthine/xanthine oxidase/ferrous chloride, but potency of calcium dobesilate to scavenge superoxide radicals was 23 times less than that of rutin that was used for comparison. However, calcium dobesilate was as potent as rutin in scavenging hydroxyl radicals generated *in vitro* via the iron-catalyzed Haber-Weiss reaction from superoxide anion (IC50 = 1.1 vs 0.7 M, respectively). In human erythrocytes, calcium dobesilate reduced phenazine methosulfate dependent lipid peroxydation, although the effect was observed at high concentration (Brunet et al., 1998a). Oral treatment with calcium dobesilate significantly protected diabetic rat retina against a free radicals mediated injury induced by ischemia/reperfusion. This was observed in an *in vivo* experiment with streptozotocininduced diabetic rats (Szabo et al., 2001). The results of these experiments support the hypothesis that the antioxidant properties of calcium dobesilate could play a role in its angioprotective properties *in vivo*. The antioxidant effects of calcium dobesilate were further investigated in relation to the oxidative status, apoptosis and in vitro proliferation of human peripheral blood mononuclear cells (PBMC) isolated from healthy donors. Calcium dobesilate alone did not modify cell growth in vitro until 10 μM. This molecule counteracted oxidative damages generated by the high reducing aldose 2-deoxy-D-ribose (dR). PBMC incubated with the reducing sugars D(-)-ribose and 2-deoxy-D-ribose (dR) exhibited characteristic patterns of apoptosis, such as DNA fragmentation and morphological changes, which can be prevented by exogenous antioxidants such as N-acetyl-L-cysteine (Barbieri et al., 1994) and/or other agents (Anderson et al., 1994). Calcium dobesilate was shown to reduce apoptosis by delaying both membrane permeability changes and DNA fragmentation. Calcium dobesilate 10 μM affected in a time-dependent dynamics several parameters representative of the cellular oxidative status. In particular, calcium dobesilate

contains a particular example of processing of calcium dobesilate.

**3. Activities found in** *In Vitro* **and animal models**

**3.1 Antioxidant and antiradical activity**

significantly increased the activity of glutathione S-transferase (GST) after three days of treatment and also, but to a lower extent, the activity of -glutamyltransferase (-GT). Both enzymes are known to be involved in the glutathione (GSH) metabolic cycle. This enzymatic behaviour was reversed at seven days of treatment, with a significant GST decrease and a - GT activation. After seven days of calcium dobesilate exposure, the intracellular GSH content was enhanced and this resulted in a dramatic decrease in lipid peroxidation, underlining the powerful antioxidant properties of calcium dobesilate in human PBMC. (Graber et al., 1998). These results indicate that *in vitro* antioxidant effects of calcium dobesilate manifest *in vivo* by reduced lipid peroxidation and contribute to the prevention of apoptosis.

#### **3.2 Angioprotective action of calcium dobesilate against reactive oxygen speciesinduced capillary permeability**

Microvascular permeability seems to be strongly increased by ROS generated *in situ*. In an *in vivo* experiment in rats, calcium dobesilate administered intraperitoneally (i.p.), intravenously (i.v.) and orally (p.o.) significantly reduced microvascular permeabilization induced by ROS in the rat peritoneal cavity. ROS were generated again either with the system xanthine / xanthine oxidase or with PMS/NADH. Microvascular permeabilization was quantified by Evans blue extravasation. The activity of calcium dobesilate was comparable to that of rutin (Brunet et al., 1998b).

#### **3.3 Enhancement of nitric oxide synthase activity in endothelial cells**

The term endothelium-derived relaxing factor was originally proposed by Robert Furchgott for a then unknown factor leading to relaxation of the smooth muscle of large arteries in response to acetylcholine. Nitric oxide NO, which is in fact a free radical, was later found to be the mediator of this response. Most of NO in the body is synthesized by the endothelial isoform of NO synthase (NOS) from its precursor L-arginine (Palmer et al., 1988a), which is inhibited by false substrates of NOS, e.g., L-NG-monomethyl arginine (L-NMMA) (Palmer et al., 1988b). NOS is a highly regulated protein and the endothelial form (eNOS) is predominantly found in endothelial cells. In them, two different isoenzymes can be expressed, depending on the activation state of these cells. In resting, non-activated endothelial cells a constitutive enzyme (ecNOS) is expressed (Moncada & Higgs, 1993) and after challenge with proinflammatory cytokines and/or bacterial endotoxin a cytokineinducible enzyme (iNOS) is expressed in addition (Suschek et al., 1993). The constitutive, calcium-dependent isoenzyme produces low amounts of NO for short periods of time (Palacios et al., 1989). This endothelium-derived NO plays a crucial role in blood pressure regulation (Rees et al., 1989), in inhibition of platelet aggregation and platelet adhesion (Radomski et al., 1987a, b), and in modulating leukocyte adhesion, an essential step early in tissue inflammation (Kubes et al., 1991, Zimmerman et al., 1992). The inducible, cytosolic, calcium-independent NO synthase is expressed only after cell activation and releases large amounts of NO for longer periods of time that functions as cytotoxic and immune regulatory effector molecule (Kröncke et al., 1995). Diabetes-induced vascular function abnormalities are besides other biochemical and morphological changes also reflected by decreased synthesis of NO (Durante et al., 1988, McVeigh et al., 1992). Magnesium 2,5 dihydroxybenzenesulfonate or magnesium dobesilate was used instead of calcium

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 317

include the upregulation of inducible NOS, cyclooxygenase-2, intercellular adhesion molecule-1 (ICAM-1), caspase-1, vascular endothelial growth factor (VEGF), and nuclear factor kappa B (NF-κB), which leads to increased production of NO, prostaglandin E2, and cytokines (Adamis & Berman, 2008, Kern, 2007). It has also been demonstrated that the adhesion of leukocytes to retinal vessels is increased in the retinas of diabetic animals, and this increase is correlated with changes in tight junction proteins and increased blood– retinal barrier (BRB) permeability (Barber et al., 2000, Klaassen et al., 2009). The increase in leukostasis is also associated with an increase in the expression of ICAM-1 by retinal endothelial cells (Miyamoto et al., 1999). NF-κB regulates the expression of adhesion molecules, such as ICAM-1, and NF-κB activation has been correlated with the increase in leukostasis and BRB breakdown in diabetic rat retinas (Joussen et al., 2002). In a study on streptozotocin-induced diabetic rats, diabetes increased the BRB permeability and retinal thickness. These changes were inhibited by Calcium dobesilate treatment. Calcium dobesilate also inhibited the increase in leukocyte adhesion to retinal vessels or endothelial cells and in ICAM-1 levels, induced by diabetes or elevated glucose. Moreover, CaD decreased oxidative stress and p38 mitogen-activated protein kinase (p38 MAPK) and NFκB activation caused by diabetes. Thus, calcium dobesilate can prevent the BRB breakdown induced by diabetes, by restoring tight junction protein levels and organization and decreasing leukocyte adhesion to retinal vessels. The protective effects of calcium dobesilate probably involves the inhibition of p38 MAPK and NF-κB activation, possibly through the

Vascular cell adhesion molecule-1 (VCAM-1) is also an important marker of the endothelial function. Similarly to ICAM-1, the concentration of its soluble form (sVCAM-1) is elevated in diabetes and diabetic retinopathy (Nowak et al., 2008, Clausen et al., 2000). The influence of calcium dobesilate on the levels of sVCAM-1 and sICAM-1 was investigated in a clinical trial in mildly obese male smokers. Endothelial dysfunction in these subjects was confirmed by means of increased levels of sVCAM-1, sICAM-1 and related parameters, but no effect of calcium dobesilate on levels of cell adhesion molecules was observed after 3 months of treatment with with 1000 mg calcium dobesilate

Calcium dobesilate was investigated for its ability to interfere with the process of angiogenesis in a mouse gelatine sponge assay using acidic fibroblast growth factor (aFGF) as an inducer of neovascularization. According to the reported results, calcium dobesilate remarkably reduced vessel ingrowth in aFGF-containing subcutaneous sponges in mice. These findings suggest that calcium dobesilate could be an effective agent in the treatment of angiogenesis-dependent diseases involving FGFs (Cuevas et al., 2005). This knowledge was successfully used in the treatment of erythematotelangiestatic rosacea, which is characterized by uncontrolled angiogenesis (Cuevas & Arrazola, 2005). Angiogenesis is, however, recently considered to be a main contributor to the pathogenesis of diabetic retinopathy (Aiello, 2003,Campochiaro, 2000; Campochiaro and Hackett, 2003). The antiangiogenic effect of calcium dobesilate can also be mediated by aminopeptidases inhibition,

inhibition of oxidative/nitrosative stress (Leal et al., 2011).

namely by inhibition of aminopeptidase N (Yang et al., 2007).

dobesilate daily(Schram et al., 2003).

**3.6 Angiogenesis inhibition**

dobesilate in an experiment concerned with investigation of influence of dobesilate on NOS activities. The reason of usage of this compound was to eliminate a direct activation of the constitutive calcium-dependent NOS by calcium ions. In search for an effect on endothelial NO production, macrovascular endothelial cells from rat aorta, microvascular endothelial cells from rat exocrine pancreatic tissue, and capillary endothelial cells from rat islets, werecultured in the presence or absence of magnesium dobesilate. The activity of ecNOS in resident cells as well as of iNOS in cytokine-activated cells was measured indirectly by recording the citrulline concentrations in culture supernatants. In each of the different endothelial cells magnesium dobesilate incubation (0.25 ± 1 mM) for 24 h led to a significant and concentration-dependent increase in ecNOS-activities. With cytokine-activated endothelial cell cultures only moderate effects were observed with little or no concentrationdependency. Addition of the NOS-inhibitor L-NMMA led to a significant suppression of citrulline formation in all cultures as an evidence for the enzyme specificity of these effects. Both iNOS- and ecNOS-specific reverse transcription and semi-quantitative polymerase chain reaction (RT-PCR) with RNA from resident or cytokine-activated endothelial cells gave no evidence for an increase in NOS-specific mRNA after MgD-treatment. Furthermore, dobesilate-mediated enhancement of NO synthesis in resting endothelial cells was not due to iNOS induction in these cells, as no iNOS-specific signal was found by RT-PCR (Suschek et al., 1997). Results of these experiments were supported by an additional study in which calcium dobesilate was found to enhance the endothelium-dependent relaxation induced by acetylcholine in rabbit isolated aorta artery. This effect was clearly endothelium dependent because, after the endothelium had been removed, the effect disappeared. The experiments were carried out on approximately 2 – 3 wide rings prepared by cutting of the arteries. The effect of calcium dobesilate was inhibited when the rings were incubated with increasing concentration of another known NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME), and this effect was reversed wit L-arginine, the substrate in NO synthesis (Ruiz et al., 1997).

#### **3.4 Influence of calcium dobesilate on apoptosis in vessel and other tissues**

Since apoptosis is closely linked with oxidation stress some aspects of anti-apoptic effects of calcium dobesilate were mentioned above in section 3.1. In a clinical study, the influence of calcium dobesilate to apoptosis of varicose veins in comparison with diosmin-hesperidin combination was investigated. Patients were treated either with calcium dobesilate or with diosmin-hesperidin six weeks prior to the surgical removal of the particular varicose vein. Tissue samples obtained from such veins of 56 patients were immunohistochemically stained with antibodies of anti-bcl-2 and anti-bax thus aimed at anti-apoptic (bcl-2) and proapoptic (bax) proteins. Significant differences in the presence of bcl-2 protein expression between the untreated patient group and the group treated with calcium dobesilate suggest that calcium dobesilate could be of benefit in treatment of vascular disorders by downregulating apoptosis (Iriz et al., 2008). On the other hand, calcium dobesilate is capable to elicit growth arrest of some types of cancer, in particular glioma (Cuevas et al., 2005) and basal cell carcinoma (Cuevas Arrazola, 2005), and induce apoptosis of their cells.

#### **3.5 Effects of calcium dobesilate on expression of adhesion molecules ICAM-1 and VCAM-1**

Diabetes causes metabolic and physiologic abnormalities in the retina, and inflammation seems to play a critical role in the development of diabetic retinopathy. Those changes

dobesilate in an experiment concerned with investigation of influence of dobesilate on NOS activities. The reason of usage of this compound was to eliminate a direct activation of the constitutive calcium-dependent NOS by calcium ions. In search for an effect on endothelial NO production, macrovascular endothelial cells from rat aorta, microvascular endothelial cells from rat exocrine pancreatic tissue, and capillary endothelial cells from rat islets, werecultured in the presence or absence of magnesium dobesilate. The activity of ecNOS in resident cells as well as of iNOS in cytokine-activated cells was measured indirectly by recording the citrulline concentrations in culture supernatants. In each of the different endothelial cells magnesium dobesilate incubation (0.25 ± 1 mM) for 24 h led to a significant and concentration-dependent increase in ecNOS-activities. With cytokine-activated endothelial cell cultures only moderate effects were observed with little or no concentrationdependency. Addition of the NOS-inhibitor L-NMMA led to a significant suppression of citrulline formation in all cultures as an evidence for the enzyme specificity of these effects. Both iNOS- and ecNOS-specific reverse transcription and semi-quantitative polymerase chain reaction (RT-PCR) with RNA from resident or cytokine-activated endothelial cells gave no evidence for an increase in NOS-specific mRNA after MgD-treatment. Furthermore, dobesilate-mediated enhancement of NO synthesis in resting endothelial cells was not due to iNOS induction in these cells, as no iNOS-specific signal was found by RT-PCR (Suschek et al., 1997). Results of these experiments were supported by an additional study in which calcium dobesilate was found to enhance the endothelium-dependent relaxation induced by acetylcholine in rabbit isolated aorta artery. This effect was clearly endothelium dependent because, after the endothelium had been removed, the effect disappeared. The experiments were carried out on approximately 2 – 3 wide rings prepared by cutting of the arteries. The effect of calcium dobesilate was inhibited when the rings were incubated with increasing concentration of another known NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME), and this effect was reversed wit L-arginine, the substrate in NO synthesis (Ruiz et al., 1997).

**3.4 Influence of calcium dobesilate on apoptosis in vessel and other tissues**

basal cell carcinoma (Cuevas Arrazola, 2005), and induce apoptosis of their cells.

**VCAM-1**

**3.5 Effects of calcium dobesilate on expression of adhesion molecules ICAM-1 and**

Diabetes causes metabolic and physiologic abnormalities in the retina, and inflammation seems to play a critical role in the development of diabetic retinopathy. Those changes

Since apoptosis is closely linked with oxidation stress some aspects of anti-apoptic effects of calcium dobesilate were mentioned above in section 3.1. In a clinical study, the influence of calcium dobesilate to apoptosis of varicose veins in comparison with diosmin-hesperidin combination was investigated. Patients were treated either with calcium dobesilate or with diosmin-hesperidin six weeks prior to the surgical removal of the particular varicose vein. Tissue samples obtained from such veins of 56 patients were immunohistochemically stained with antibodies of anti-bcl-2 and anti-bax thus aimed at anti-apoptic (bcl-2) and proapoptic (bax) proteins. Significant differences in the presence of bcl-2 protein expression between the untreated patient group and the group treated with calcium dobesilate suggest that calcium dobesilate could be of benefit in treatment of vascular disorders by downregulating apoptosis (Iriz et al., 2008). On the other hand, calcium dobesilate is capable to elicit growth arrest of some types of cancer, in particular glioma (Cuevas et al., 2005) and include the upregulation of inducible NOS, cyclooxygenase-2, intercellular adhesion molecule-1 (ICAM-1), caspase-1, vascular endothelial growth factor (VEGF), and nuclear factor kappa B (NF-κB), which leads to increased production of NO, prostaglandin E2, and cytokines (Adamis & Berman, 2008, Kern, 2007). It has also been demonstrated that the adhesion of leukocytes to retinal vessels is increased in the retinas of diabetic animals, and this increase is correlated with changes in tight junction proteins and increased blood– retinal barrier (BRB) permeability (Barber et al., 2000, Klaassen et al., 2009). The increase in leukostasis is also associated with an increase in the expression of ICAM-1 by retinal endothelial cells (Miyamoto et al., 1999). NF-κB regulates the expression of adhesion molecules, such as ICAM-1, and NF-κB activation has been correlated with the increase in leukostasis and BRB breakdown in diabetic rat retinas (Joussen et al., 2002). In a study on streptozotocin-induced diabetic rats, diabetes increased the BRB permeability and retinal thickness. These changes were inhibited by Calcium dobesilate treatment. Calcium dobesilate also inhibited the increase in leukocyte adhesion to retinal vessels or endothelial cells and in ICAM-1 levels, induced by diabetes or elevated glucose. Moreover, CaD decreased oxidative stress and p38 mitogen-activated protein kinase (p38 MAPK) and NFκB activation caused by diabetes. Thus, calcium dobesilate can prevent the BRB breakdown induced by diabetes, by restoring tight junction protein levels and organization and decreasing leukocyte adhesion to retinal vessels. The protective effects of calcium dobesilate probably involves the inhibition of p38 MAPK and NF-κB activation, possibly through the inhibition of oxidative/nitrosative stress (Leal et al., 2011).

Vascular cell adhesion molecule-1 (VCAM-1) is also an important marker of the endothelial function. Similarly to ICAM-1, the concentration of its soluble form (sVCAM-1) is elevated in diabetes and diabetic retinopathy (Nowak et al., 2008, Clausen et al., 2000). The influence of calcium dobesilate on the levels of sVCAM-1 and sICAM-1 was investigated in a clinical trial in mildly obese male smokers. Endothelial dysfunction in these subjects was confirmed by means of increased levels of sVCAM-1, sICAM-1 and related parameters, but no effect of calcium dobesilate on levels of cell adhesion molecules was observed after 3 months of treatment with with 1000 mg calcium dobesilate dobesilate daily(Schram et al., 2003).

#### **3.6 Angiogenesis inhibition**

Calcium dobesilate was investigated for its ability to interfere with the process of angiogenesis in a mouse gelatine sponge assay using acidic fibroblast growth factor (aFGF) as an inducer of neovascularization. According to the reported results, calcium dobesilate remarkably reduced vessel ingrowth in aFGF-containing subcutaneous sponges in mice. These findings suggest that calcium dobesilate could be an effective agent in the treatment of angiogenesis-dependent diseases involving FGFs (Cuevas et al., 2005). This knowledge was successfully used in the treatment of erythematotelangiestatic rosacea, which is characterized by uncontrolled angiogenesis (Cuevas & Arrazola, 2005). Angiogenesis is, however, recently considered to be a main contributor to the pathogenesis of diabetic retinopathy (Aiello, 2003,Campochiaro, 2000; Campochiaro and Hackett, 2003). The antiangiogenic effect of calcium dobesilate can also be mediated by aminopeptidases inhibition, namely by inhibition of aminopeptidase N (Yang et al., 2007).

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 319

vasoconstrictor and mitogenic endothelium derived peptide, and has been considered as a marker for endothelial damage and potential contributor to the developmentof the atherogenic process. Increased circulating ET-1 levels was found in patients with atherosclerosis, as well as in patients with Type 2 diabetes mellitus suggesting arole in the pathogenesis of these disorders (Ak et al., 2001). Plasma ET-1 plays also an important role in the whole patho-physiological process of diabetic retinopathy. Its plasma concentrations correlate to the severity of the disease, measures of their plasma concentrations can help to predict the severity of the disease. They also enable to distinguish between proliferative and non-proliferative diabetic retinopathy (Cao et al., 2009). In a clinical study, the plasma ET-1 concentrations were determined in 45 diabetes mellitus patients. The changes of ET-1 in 20 diabetic retinopathy patients before and after treatment with calcium dobesilate and 30 normal controls were observed. The level of plasma endothelin was higher in diabetes mellitus patients than that of the controls, which was even higher in diabetic retinopathy. After treatment with calcium dobesilate, the plasma ET-1 level decreased significantly

Studies on the metabolism and pharmacokinetics of calcium dobesilate were carried out by Benakis and colleagues (Benakis et al., 1974). They reported the results of blood levels of calcium dobesilate labeled with 35S isotope, protein binding and urinary excretion in humans. The studies in humans were performed by the administration of the drug *p.o.* or *i.v.* After *i.v.* medication, 500 mg, the maximum value is obtained 5 min after administration and is about 65 mg/ml. This value of dicreases rapidly, the plasma half-life being 1 hr. After administration by the oral route, 500 mg in a capsule, the maximum value was obtained at the 6th hour after medication and is about 8mg/ml, and a plateau was obtained between the 3rd and the 10th hour. Levels decreased slowly and were undetectable 24 hours after administration. Intestinal absorption was 15% per hour during the first 7 hours and then decreased to 5% per hour. More than 80% of the drug is absorbed in the first 8 hours. The drug is 20–25% protein bound. The specific affinity of the drug to aggregated and nonaggregated platelets has been demonstrated. Calcium dobesilate does not cross the blood-brain barrier. Urinary elimination in the first 24 hours reaches 75% after *i.v.*

**5. Clinical findings and usage of calcium dobesilate in prevention and**

While the results of various *in vitro* experiments suggest that calcium dobesilate would have to be effective in the treatment of diabetic retinopathy, the results of clinical trials are ambiguous. One of the first clinical studies was a double-blind, randomized trial, which lasted for 2 years. The authors investigated the efficacy of calcium dobesilate on diabetic retinopathy in 51 patients, 17 were on placebo. The statistical analysis of the results indicated that calcium dobesilate acts as a potent angioprotector, capable of preventing both intra. and extraretinal hemorrhages. The drug also lowered the incidence of exudate

**4. Pharmacokinetics and metabolism of calcium dobesilate**

(Zhong Guo, 1997).

medication and 50% after oral medication.

**treatment of diabetic retinopathy**

**5.1 Results of clinical studies**

#### **3.7 Reduction of retinal albumin leakage by calcium dobesilate**

The action of calcium dobesilate on retinal albumin leakage in streptozotocin-diabetic rats was investigated together with relevant in vivo retinal antioxidant and permeability markers, i.e., carboxymethyl-lysine-advanced glycation end product (CML-AGE) formation and vascular endothelial cell growth factor (VEGF) overexpression. Twenty days after streptozotocin administration, diabetic rats were treated for 10 days with calcium dobesilate (100 mg/kg/day per os) or vehicle. Retinal albumin leakage, CML-AGE formation, and VEGF overexpression were evaluated by immunohistochemistry of frozen eye sections. Diabetic rats exhibited dramatic increases in retinal albumin leakage (31% of positive vessels vs. 0.2% in nondiabetic rats, CML-AGE retinal occurrence (40±3% vs. undetectable positive vessels), and retinal VEGF protein expression (14.6±1.1 vs. 3.5±0.5 VEGF-positive spots/field). Calcium dobesilate significantly reduced retinal albumin leakage (by 70%), retinal CML-AGEs contents (by 62%), and retinal VEGF expression (by 69.4%). In conclusion, calcium dobesilate orally given to diabetic rats markedly reduced retinal hyperpermeability, CML-AGE contents, and VEGF overexpression. These results strongly suggest that calcium dobesilate stabilizes blood–retinal barrier in diabetic retinopathy (Rota et al., 2004).

#### **3.8 Influence of calcium dobesilate on platelets and blood viscosity**

Platelet-active drugs are in general of potential benefit in the prevention of diabetic microangiopathy. Calcium dobesilate was shown to reduce aggregation and the release reaction induced by thrombin and collagen in rabbit platelets (Michal Gotti, 1988). Calcium dobesilate also increased platelet cAMP concentrations *in vitro* and *ex vivo* probably through activation of adenylate cyclase (Michal and Gotti, 1988). In addition, this drug reduced platelet electrophoretic mobility (Heidrich et al., 1983), and it inhibited, in a timeand concentration-dependent manner, platelet-activating factor (PAF) production by the EA926 endothelial cell line stimulated by thrombin (Bussolino et al., 1986). The effects of PAF on the microvasculature bed of glomerular or pulmonary microcirculation suggest that PAF might play a role in microcirculation disease. The rheological properties of blood in diabetes mellitus have received increasing attention since Skovborg and colleagues demonstrated elevation of whole-blood viscosity in diabetics (Skovborg et al., 1966). In particular, evidence has accumulated that abnormal blood viscosity plays a role in the pathogenesis of diabetic retinopathy. Increased blood viscosity in diabetes mellitus has been attributed to changes in plasma protein composition (Barnes et al., 1977, Hoare et al., 1976, Hudomel et al., 1977, Skovborg et al., 1966); and to increased aggregation of red blood cells (McMillan, 1976). The mechanism by which hyperviscosity contributes to the deterioration of the microcirculation in the retina and other organs in diabetics is that, by increasing the resistance to blood flow, it causes blood stasis, especially in the capillaries and postcapillary venules, which are the sites where the very early lesions of diabetes microangiopathy characteristically appear. In some studies, calcium dobesilate has been demonstrated to decrease hyperviscosity in blood (Barras Graf, 1980, Vojnikovic, 1991), perhaps through a fibrinogen-lowering effect (Barras Graf, 1980, Vinnazzer Hachen, 1987).

#### **3.9 Influence of calcium dobesilate on plasma levels of endothelin**

Endothelin-1 (ET-1) was discovered by Yanagisawa and colleagues in 1988 (Yanagisava et al., 1988) in the supernatant of aortic endothelial cells. ET-1 is a potentand prolonged

The action of calcium dobesilate on retinal albumin leakage in streptozotocin-diabetic rats was investigated together with relevant in vivo retinal antioxidant and permeability markers, i.e., carboxymethyl-lysine-advanced glycation end product (CML-AGE) formation and vascular endothelial cell growth factor (VEGF) overexpression. Twenty days after streptozotocin administration, diabetic rats were treated for 10 days with calcium dobesilate (100 mg/kg/day per os) or vehicle. Retinal albumin leakage, CML-AGE formation, and VEGF overexpression were evaluated by immunohistochemistry of frozen eye sections. Diabetic rats exhibited dramatic increases in retinal albumin leakage (31% of positive vessels vs. 0.2% in nondiabetic rats, CML-AGE retinal occurrence (40±3% vs. undetectable positive vessels), and retinal VEGF protein expression (14.6±1.1 vs. 3.5±0.5 VEGF-positive spots/field). Calcium dobesilate significantly reduced retinal albumin leakage (by 70%), retinal CML-AGEs contents (by 62%), and retinal VEGF expression (by 69.4%). In conclusion, calcium dobesilate orally given to diabetic rats markedly reduced retinal hyperpermeability, CML-AGE contents, and VEGF overexpression. These results strongly suggest that calcium dobesilate stabilizes blood–retinal

Platelet-active drugs are in general of potential benefit in the prevention of diabetic microangiopathy. Calcium dobesilate was shown to reduce aggregation and the release reaction induced by thrombin and collagen in rabbit platelets (Michal Gotti, 1988). Calcium dobesilate also increased platelet cAMP concentrations *in vitro* and *ex vivo* probably through activation of adenylate cyclase (Michal and Gotti, 1988). In addition, this drug reduced platelet electrophoretic mobility (Heidrich et al., 1983), and it inhibited, in a timeand concentration-dependent manner, platelet-activating factor (PAF) production by the EA926 endothelial cell line stimulated by thrombin (Bussolino et al., 1986). The effects of PAF on the microvasculature bed of glomerular or pulmonary microcirculation suggest that PAF might play a role in microcirculation disease. The rheological properties of blood in diabetes mellitus have received increasing attention since Skovborg and colleagues demonstrated elevation of whole-blood viscosity in diabetics (Skovborg et al., 1966). In particular, evidence has accumulated that abnormal blood viscosity plays a role in the pathogenesis of diabetic retinopathy. Increased blood viscosity in diabetes mellitus has been attributed to changes in plasma protein composition (Barnes et al., 1977, Hoare et al., 1976, Hudomel et al., 1977, Skovborg et al., 1966); and to increased aggregation of red blood cells (McMillan, 1976). The mechanism by which hyperviscosity contributes to the deterioration of the microcirculation in the retina and other organs in diabetics is that, by increasing the resistance to blood flow, it causes blood stasis, especially in the capillaries and postcapillary venules, which are the sites where the very early lesions of diabetes microangiopathy characteristically appear. In some studies, calcium dobesilate has been demonstrated to decrease hyperviscosity in blood (Barras Graf, 1980, Vojnikovic, 1991), perhaps through a

**3.7 Reduction of retinal albumin leakage by calcium dobesilate**

**3.8 Influence of calcium dobesilate on platelets and blood viscosity**

fibrinogen-lowering effect (Barras Graf, 1980, Vinnazzer Hachen, 1987).

Endothelin-1 (ET-1) was discovered by Yanagisawa and colleagues in 1988 (Yanagisava et al., 1988) in the supernatant of aortic endothelial cells. ET-1 is a potentand prolonged

**3.9 Influence of calcium dobesilate on plasma levels of endothelin**

barrier in diabetic retinopathy (Rota et al., 2004).

vasoconstrictor and mitogenic endothelium derived peptide, and has been considered as a marker for endothelial damage and potential contributor to the developmentof the atherogenic process. Increased circulating ET-1 levels was found in patients with atherosclerosis, as well as in patients with Type 2 diabetes mellitus suggesting arole in the pathogenesis of these disorders (Ak et al., 2001). Plasma ET-1 plays also an important role in the whole patho-physiological process of diabetic retinopathy. Its plasma concentrations correlate to the severity of the disease, measures of their plasma concentrations can help to predict the severity of the disease. They also enable to distinguish between proliferative and non-proliferative diabetic retinopathy (Cao et al., 2009). In a clinical study, the plasma ET-1 concentrations were determined in 45 diabetes mellitus patients. The changes of ET-1 in 20 diabetic retinopathy patients before and after treatment with calcium dobesilate and 30 normal controls were observed. The level of plasma endothelin was higher in diabetes mellitus patients than that of the controls, which was even higher in diabetic retinopathy. After treatment with calcium dobesilate, the plasma ET-1 level decreased significantly (Zhong Guo, 1997).

#### **4. Pharmacokinetics and metabolism of calcium dobesilate**

Studies on the metabolism and pharmacokinetics of calcium dobesilate were carried out by Benakis and colleagues (Benakis et al., 1974). They reported the results of blood levels of calcium dobesilate labeled with 35S isotope, protein binding and urinary excretion in humans. The studies in humans were performed by the administration of the drug *p.o.* or *i.v.* After *i.v.* medication, 500 mg, the maximum value is obtained 5 min after administration and is about 65 mg/ml. This value of dicreases rapidly, the plasma half-life being 1 hr. After administration by the oral route, 500 mg in a capsule, the maximum value was obtained at the 6th hour after medication and is about 8mg/ml, and a plateau was obtained between the 3rd and the 10th hour. Levels decreased slowly and were undetectable 24 hours after administration. Intestinal absorption was 15% per hour during the first 7 hours and then decreased to 5% per hour. More than 80% of the drug is absorbed in the first 8 hours. The drug is 20–25% protein bound. The specific affinity of the drug to aggregated and nonaggregated platelets has been demonstrated. Calcium dobesilate does not cross the blood-brain barrier. Urinary elimination in the first 24 hours reaches 75% after *i.v.* medication and 50% after oral medication.

#### **5. Clinical findings and usage of calcium dobesilate in prevention and treatment of diabetic retinopathy**

#### **5.1 Results of clinical studies**

While the results of various *in vitro* experiments suggest that calcium dobesilate would have to be effective in the treatment of diabetic retinopathy, the results of clinical trials are ambiguous. One of the first clinical studies was a double-blind, randomized trial, which lasted for 2 years. The authors investigated the efficacy of calcium dobesilate on diabetic retinopathy in 51 patients, 17 were on placebo. The statistical analysis of the results indicated that calcium dobesilate acts as a potent angioprotector, capable of preventing both intra. and extraretinal hemorrhages. The drug also lowered the incidence of exudate

Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy 321

effect of calcium dobesilate. The estimated prevalence of agranulocytosis is 0.32 cases/million treated patients, i.e. ten times less than the calculated prevalence of agranulocytosis in the general population (Allain et al., 2004). Moreover, there is no case report that would attribute agranulocytosis clearly to calcium dobesilate during a simple

Calcium dobesilate is predominantly administered *p.o.* in uncoated tablets. Initial dosage in early stages of microangiopathies, namely diabetic retinopathy, is 250 mg calcium dobesilate three times a day (three tablets per day). After 2-3 weeks it is possible to decrease dosage to the keeping level 250-500 mg calcium dobesilate per day. Diminished performance of liver or kideys has no impact to dosage of calcium dobesilate (Medicinal products database of the

Except of usually administerd oral tablets, some topic preparations of calcium dobesilate have also been reported. Ocular preparations for a local treatment of diabetic retinopathy and related disorders like glaucoma are the matter of the patent application of Velpandian (Velpandian, 2006). The simpliest eye solution, which is the Composition I of the Example 1 of this patent, contain 1 % weight-volume (w/v) calcium dobesilate, 0.76 % w/v sodium chloride for isotonisation and 0.1 % w/v sodium metabisulfite as an antioxidant. The Composition II is similar but contains only 0.70 % w/v sodium chloride and furtherly 0.4 % w/v hydroxypropylmethylcellulose as an viscosity-increasing agent. The Compositions III a IV are water insoluble and water soluble eye oitments respectively. The micronized form of calcium dobesilate in concentration 1 % w/v is used for preparation of both. The vehicle for water insoluble oitment is the white petrolatum mixed with a mineral oil, for the water soluble one it is a mixture of polyethylene glycols. Both oitments contain suitable antimicrobial preservatives in concentration 0.01 % w/v and 0.001 % w/v respectively. The composition V is a controlled-release gel based on a suitable gel-forming polymer and

Calcium dobesilate is one of the oldest drugs used in the treatment of diabetic retinopathy. The first reports concerning its usage appeared in the late 1960th (Sevin & Cuendet, 1969a, b). Its mechanisms of action have been gradually elucidated. Many of them are related to its reactivity as a reducing agent. Now it is known that they include lowering of reactive oxygen species-induced capillary permeability, enhancement of nitric oxide synthase activity in endothelial cells, influence of calcium dobesilate on apoptosis in vessel and other tissues, effects of calcium dobesilate on expression of cellular adhesion molecules, angiogenesis inhibition, reduction of retinal albumin leakage, influence of calcium dobesilate on platelets and blood viscosity, influence of calcium dobesilate on plasma levels of endothelin and others. Despite certain doubts of its efficiency originating from results of some clinical trials calcium dobesilate still remains the only angioprotective agent that

reduces the progression of diabetic retinopathy (Garay et al., 2005).

treatment of diabetic retinopathy.

State institute for Drug Control, 2011).

contain also 1 % w/v calcium dobesilate.

**8. Conclusion**

**7.1 Intraocular preparations of calcium dobesilate**

**7. Dosage and aplication forms of calcium dobesilate**